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ABSTRACT 
 
              
Nitric oxide donors in labor management 
Maria Bullarbo 
Department of Obstetrics and Gynecology 
Institute of Clinical Sciences 
 
Background: Nitric oxide (NO), a free radical with ultra-short half-life synthesized from L- 
arginine by the enzyme nitric oxide synthase (NOS), is in the human involved in many 
physiological and pathophysiological processes, including different reproductive processes. 
During pregnancy NO is produced endogenously in the human uterine cervix and placenta. 
Different effects of NO can be studied by administering NO donors.  
Aims and methods: The aims of the thesis were to perform experimental and clinical studies 
on late pregnant women to examine the effects of NO donors on cervical ripening and labor 
induction and to evaluate possible effects of NO on the management of retained placenta. In 
Paper I the effects of the NO donor isosorbide mononitrate (IMN) administered vaginally 
were examined by measuring cervical distensibility using a cervical tonometer. In addition, 
maternal and fetal side effects of the medication were evaluated. In Paper II the efficiency of 
vaginally adminstered IMN to induce cervical ripening and labor induction in an outpatient 
setting was examined. The safety and side effects of this treatment were also evaluated. 
In Paper III cervical biopsies were obtained prior to elective caesarean section following 
vaginal administration of IMN. Western blotting was used for semiquantitative measurements 
of cyclooxygenase-1 and -2 (COX-1 and COX-2), enzymes involved in prostaglandin 
synthesis as well as cervical ripening. Immunohistochemistry was used for localizing these 
enzymes within the cervical tissue. Paper IV describes the efficiency of sequential treatment 
with oxytocin and nitroglycerin for management of retained placenta. 
Results: Treatment with IMN resulted in a significantly increased cervical distensibility. 
Headache and palpitations of little to moderate intensity were common maternal side effects.  
A significant decrease in maternal blood pressure and increase in pulse rate were registered. 
However, the effects were modest and not of clinical importance. No fetal side effects were 
observed according to CTG, Doppler ultrasound, Apgar score and umbilical pH. Vaginally 
administered IMN seemed to be effective in promoting labor induction within 24 hours (22 
patients compared to 8 in the placebo group). There were no differences in fetal side effects 
and the rate of caesarean section between women treated with IMN and women in the placebo 
group. Semiquantitative measurements by immunoblotting revealed increased expression of 
COX-2, but not of COX-1 in the NO donor group compared to placebo group. 
Immunohistchemistry showed similar localizations of COX-1 and COX-2 in the two groups. 
Sublingually administered nitroglycerin in combination with oxytocin resulted in successfully 
delivered placenta among all 12 women compared to only 1 woman in the control group. 
Maternal hemodynamic effects were mild to moderate. Blood loss was increased in women 
who needed manual removal of placenta.  
Conclusion: The data suggest that IMN administered vaginally at term and postterm for 
cervical ripening and labor induction seems to be effective and safe. Combined treatment with 
oxytocin and nitroglycerin seems to promote detachment of retained placenta.  
Key Words: cervical ripening, labor induction, nitric oxide donor, retained placenta. 
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 1   
INTRODUCTION 
 
 
Labor is one of the most exciting events in life. Most often the process follows a normal 
pattern and results in delivery of a healthy child. Many steps are normally involved from 
spontaneous start of labor at term to partus followed by delivery of placenta. This thesis is 
focused on problems concerning onset of labor and delivery of placenta as well as possible 
effects of nitric oxide (NO) donors for management of problems related to these stages of 
labor.  
 
There may be situations when induction of labor is necessary, as it could be hazardous to wait 
for spontaneous onset of labor, e.g. preeclampsia, severe hypertension, postterm pregnancy, 
diabetes mellitus, multiple pregnancy, intrauterine growth retardation or oligohydramniosis. If 
the cervix is ripe the most common methods of labor induction are amniotomy and/or 
oxytocin infusion. In cases the cervix is unripe it is necessary to use a local medical or 
mechanical treatment to achieve cervical ripening. The most common medical agent is 
prostaglandin (PG) administered vaginally or intracervically. However, PGs may be 
associated with side effects. Thus, in approximately 5% of treated women uterine 
hyperstimulation is registered. Furthermore, the treatment is not always effective and often it 
has to be repeated. In these cases the risk of failed induction is increased.  
 
It is desirable to find a treatment that is more effective and not associated with 
hyperstimulation. Nitric oxide, a free radical with extremely short half-life, is endogenously 
produced in the human uterine cervix (Tschugguel et al, 1999) and has been shown to be up-
regulated at term pregnancy (Ledingham et al, 2000; Väisänen-Tommiska et al, 2003). Thus, 
NO is thought to play a role in cervical ripening (Chwalisz, 1997; 1998) and several studies 
on vaginally administered NO donors have shown ripening effects of the treatment (Thomson 
et al, 1997; Facchinetti et al, 2000). The present study aims to give some aspects on the role 
of NO donors on cervical ripening and labor induction. 
 
The third stage is defined as the interval from birth of the infant to delivery of the placenta. It 
normally lasts for approximately 6 minutes. In about 3% of all deliveries the placenta does not 
detach spontaneously. In such cases, a variety of medical treatments to avoid manual 
extraction in regional or general anaesthesia may be applied. Oxytocin as well as PGs, both 
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promoting uterine contractions, are the most common agents for management of retained 
placenta. However, administration of these agents is not always effective. Treatment with NO 
donors, such as nitroglycerin, has in some trials shown to have effect on management of 
retained placenta. Few studies have been carried out in order to identify the mechanisms of 
retained placenta. Herman and co-workers, carrying out ultrasonographic examinations, 
concluded that it is not until the retroplacental part of the uterine body contracts that the 
placenta detaches. This procedure seems to be independent of oxytocin administration 
(Herman et al, 1993). On the other hand, NO is upregulated in the amniotic membranes 
during labor (Ticconi et al, 2004), a mechanism that could play a role in the third stage of 
labor. In this thesis the possible effect of nitroglycerin for management of retained placenta 
when administered sublingually in combination with oxytocin was investigated.  
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BACKGROUND-review of the literature 
 
 
NITRIC OXIDE 
 
The nitric oxide molecule 
Nitric oxide (NO) is one of the 10 smallest molecules in nature, detected by Joseph Priestly 
more than 200 years ago. The chemical formula is NO. It is polar, heavier than air and 
paramagnetic due to an unpaired electron. Such substances are usually called free radicals. Its 
melting point is at -164ºC while its boiling point is at -152ºC. It is colorless, highly reactive 
with an ultrashort half-life of 4-8 seconds.  
 
       
 
Figure 1. The nitric oxide molecule, also called nitrogen monoxide. 
 
Nitric oxide has for years been known as a nuisance. It is a poisonous gas with adverse effects 
on the environment. Produced in internal combustion engines and electrical generating 
stations NO has been implicated in depletion of the ozone layer, formation of photochemical 
smog, and acid rain. In 1916 Mitchell and co-workers observed that oxides of nitrogen were 
produced by mammals. Twelve years later, in 1928, Tannenbaum and co-workers confirmed 
that nitrite and nitrate are formed by endogenous synthesis in the human intestine. Despite 
these discoveries NO was for many decades commonly regarded by chemists and 
environmentalists as a very toxic molecule with only negative effects. In 1978 Murad and co-
workers demonstrated that the vasodilatory effect of nitroglycerin and several other nitrates 
was mediated by NO. Furthermore, in 1980 Furchgott and Zawadzki provided evidence that 
acetylcholine-induced relaxation of vascular rings was mediated by a non-prostanoid, 
endothelium dependent relaxing factor (EDRF). Five years later, Stuehr and Marletta 
discovered that macrophages synthesize nitrite/nitrate. Independently and simultaneously, 
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Palmer and co-workers and Ignarro and co-workers in 1987 provided evidence that EDRF is 
NO. Since then the research on the biology and functions of NO has substantially increased. 
In 1998 Furchgott, Ignarro and Murad were rewarded with the Nobel Prize in Medicine for 
their discoveries regarding NO. The discovery that NO can penetrate cell membranes and 
regulate the function of other cells was an entirely new principle for signalling in the human 
organism.  
 
Synthesis of nitric oxide 
Nitric oxide is synthesized intracellularily from the amino acid L-arginine (Palmer et al, 
1988). This reaction is catalyzed by a family of enzymes, known as nitric oxide synthases 
(NOS) (Palmer and Moncada, 1989). These enzymes are structurally complex haemproteins 
with properties similar to cytochrome P-450 reductase (Marletta, 1994). NOS require a 
number of cofactors, such as tightly bound flavoproteins and tetrahydrobiopterin, while the 
production of NO itself requires the co-substrate oxygen and nicotinamide adenine 
dinucleotide phosphate (NAPDH) (Zapol et al, 1994). The reaction goes through a two-step 
conversion of L-arginine to NO and L-citrulline via Nω-hydroxy-L-arginine as an intermediate 
product (Aktan, 2004) (Figure 2). 
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Figure 2. Biosynthesis of NO from L-arginine through a two-step conversion to  
L-citrulline. 
 
Three major isoforms of NOS have been identified. These isoforms are encoded by separate 
genes, located on chromosomes 7, 12 and 17 (Knowles et al, 1989; Lamas et al, 1992; 
Löwenstein et al, 1992; Knowles and Moncada, 1994). They are neuronal NOS (nNOS, type 
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1) and endothelial NOS (eNOS, type 3), which both are expressed constitutively. In addition, 
a macrophage-derived form, inducible NOS (iNOS, type 2) that is induced by endotoxin and 
inflammatory mediators, such as cytokines and lipopolysaccharides has been identified (Liu, 
1993; Morris and Billiar, 1994). Both nNOS and eNOS require calcium/calmodulin for 
activation (Griffith and Stuehr, 1995; Snyder, 1995). Although iNOS is said to be calmodulin 
independent, calmodulin is tightly bound to each subunit of the isoform (Cho et al, 1992). 
This classification might be a simplification since other isoforms of NOS also have been 
described. Thus, reports of calcium-dependent isoforms that are inducible as well as calcium-
independent isoforms that are constitutive have been published (Radomski et al, 1991; Palmer 
et al, 1992). Inducible NOS was initially cloned from activated macrophages (Xie et al, 1992) 
and later described in human macrophages (Moilanen et al, 1997; Aktan, 2004) (Table 1). 
Nitric oxide production under the influence of iNOS occurs with a delay of 6-8 hours after 
stimulation. Once induced, iNOS is active for hours or even days and produces NO in 1000-
fold larger quantities than the constitutive forms (Moncada and Higgs, 1993; Beck et al, 
1999).  
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 nNOS 
constitutive 
eNOS 
constitutive 
iNOS 
inducible 
quantity of NO 
release 
10-12 
(pmol) 
10-12 
(pmol) 
10-9 
(nmol) 
location 
chromosome number 
12 7 17 
cellular compartment cytosolic membrane-bound cytosolic 
celltype neurons endothelium 
platelets 
endocardium 
myocardium 
macrophages 
smooth muscle cells 
epithelial cells 
endocardium 
myocardium 
hepatocytes 
astrocytes 
fibroblasts 
chondrocytes 
osteoblasts/-clasts 
target organs nerves vascular smooth 
muscle 
microbes 
activation ca-dependent ca-dependent ca-independent 
expression constitutive constitutive induction by 
LPS/cytokines 
activators sex hormones, 
cytokines, stress, 
physical exercise 
acetylcholine, 
bradykinin, sex 
hormones, 
mechanical pressure, 
physical exercise 
inflammatory 
mediators, cytokines, 
kinases, LPS, PG 
 
Table 1.  Properties of constitutive and inducible isoforms of NOS. 
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Nitric oxide and its mechanisms of biological action  
Nitric oxide is a highly reactive molecule with a half-life of 4-8 seconds. It is soluble both in 
water and lipid and is therefore highly diffucible through membranes. It is the first example of 
a completely new signalling molecule quite different from the classical mediator concept 
(Nathan, 1992; Snyder, 1992). Whereas NO is a simple radical gas which forms covalent 
bonds fairly easily, classical mediators have complex structures and depend for their action on 
a complementary fit to a specific receptor.   
 
Nitric oxide has several targets of action, which can be divided into at least following major 
groups: 
 1) Through cyclic guanosine monophosphate (cGMP).  
 2) Interaction through cGMP-independent mechanisms. 
 3) Interaction with free radicals. 
 
1) Cyclic GMP. The physiologically most relevant action of NO is the activation of soluble 
guanylatcyclase by nitrosation of its haem moiety (Ignarro, 1990). Cyclic GMP regulates 
intracellular calcium concentrations, which mediate physiological functions of NO smooth 
muscle relaxation and platelet aggregation. The subsequent increase in cGMP levels alters the 
activity of three main target proteins: cGMP-regulated ion channels, cGMP-regulated 
phosphodiesterases and cGMP-dependent protein kinases (Schmidt et al, 1993).  
 
2) Interaction through cGMP-independent mechanisms. One of the most important of these 
involves the nitrosylation of the target proteins. In this way NO can influence other enzymes 
such as cytochrome oxidase (Brown, 1997), ribonucleotide reductase (Lepoivre et al, 1990) 
and cyclooxygenase (Salvemini, 1997) and hence influence cellular respiration, DNA 
synthesis and inflammatory and immune responses. Endogenous NO enhances PG production 
in inflamed tissues (Salvemini, 1994). Nitric oxide may also affect smooth muscle relaxation, 
cell signalling and phagocytosis by their direct activation of gene transcription (Nathan, 1992; 
Umansky et al, 1988). Furthermore, there is increasing evidence that NO can directly regulate 
gene expression by modulating the activity of transcription factors such as NFкB and the 
activator protein 1 (AP-1) (Sen and Packer, 1996). Since NFкB inhibits progesterone receptor 
action via protein-protein interaction (Kalkhoven et al, 1996) NO may therefore modulate 
progesterone responses in the reproductive tract. The list of genes under the regulatory control 
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of NO is expanding, including those involved in the extracellular matrix protein (MMP) 
synthesis and their degrading enzymes (Chatziantoniu et al, 1998; Sasaki et al, 1998), 
cytokines, and chemokines, such as IL-8 (Villarete and Remick, 1995). However, higher 
concentrations of NO may also interact directly with MMPs (Trachtman et al, 1996). Finally, 
at high concentrations NO plays a role in apoptotic cell death. An increased apoptosis 
following exogenous application of NO donors or iNOS induction has been described in 
different celltypes, such as macrophages and mesangial cells (Brüne et al, 1998).  
 
3) Interaction with free radicals. Nitric oxide can interact with free radicals such as superoxide 
anion and free thiols to mediate its effect. The reaction with superoxide anion results in the 
formation of toxic hydroxyl radicals and peroxynitrite that are involved in host defence 
responses. Interactions between thiols and NO result in the formation of S-nitrosothiol 
derivatives that are more stable and prolong the effects of NO in vivo (Clancy et al, 1994; Jia 
et al, 1996).  
 
Detection of nitric oxide 
As a consequence of the short half-life of NO its detection is difficult both in vivo and in vitro. 
Nitric oxide was first quantified in 1987 by Palmer and co-workers who used a 
chemiluminescence assay. In vitro, detection of NO has been possible by using a rapid 
response chemiluminescence analyzer (Lee et al, 2000) or by using NO specific 
microelectrodes (Tsukahara et al, 1993). Indirect measurement of NO can be done by 
measuring the conversion of radiolabeled arginine to citrulline or by measuring the formation 
of cGMP (Ogden and Moore, 1995). Another method of measuring NO production is by 
detecting positive NADPH diaphorase activity (Rosselli et al, 1996; Ekerhovd et al, 1997). In 
vivo, it is even more challenging to assess NO production. Among experimental studies on 
endothelial vasomotor function, indirectly measuring NO release, pletysmography and 
pulsewave analysis have been used (Benjamin et al, 1995; Wilkinson et al, 2002). Stefansson 
and colleagues have described a new method for monitoring NO production in vivo using 
Teflon membrane microdialysis (electron spin resonance). This Teflon membrane allows only 
gaseous molecules (NO) to penetrate and the technique has been used in renal studies. The 
expression of NOS can be assessed by semiquantitative measurements like Western blotting 
or reverse transcriptase-polymerase chain reaction (RT-PCR). Immunohistochemical studies 
can also be used for expression of NO metabolites and NOS (Tschugguel et al, 1999; 
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Alderton et al, 2001; Aktan, 2004; Törnblom et al, 2005). The NO metabolites nitrite and 
nitrate can be assessed by the use of the Griess reaction (Nakatsuka et al, 2000; Väisänen-
Tommiska et al, 2003; 2004). Griess reagent forms azo dye with nitrite, which can be 
spectrophotometrically measured (Green et al, 1982). In studies on NO donors and their 
effects on different enzymes, such as cyclooxygenases and MMPs, Western blotting, RT-
PCR, radioimmunoassay, ELISA, and immunohistochemistry can be used for analysis 
(Salvemini et al, 1993; Ledingham et al, 1999b; Stygar et al, 2002). 
 
General effects of nitric oxide 
Nitric oxide is an important physiological and pathophysiological factor in cardiovascular, 
nervous and immunological systems (Moncada and Higgs, 1993; Alderton et al, 2001; Aktan, 
2004). It reduces blood pressure by vascular dilatation and smooth muscle relaxation and 
inhibits platelet aggregation. It stimulates angiogenesis and seems to play a role in placental 
trophoblast villi (DiIulio et al, 1995; Ramsay et al, 1996). The wavelike motions of the 
gastrointestinal tract are aided by the relaxing effect of NO on the smooth muscle in its walls 
(Vanderwinden, 1994). It is an important neurotransmitter. Nitric oxide has also been 
associated with processes of learning, sleeping, pain as well as neurological disorders. Nitric 
oxide is involved in the physiological regulation of renal function (Haynes et al, 1997). It is 
involved in wound healing (Schaffer et al, 1996) and normal lung function (Lehtimäki et al, 
2005) as well as being a toxic agent in malignant and anti-inflammatory disorders (Moncada 
and Higgs, 1993; Alderton et al, 2001). Nitric oxide affects secretion from several endocrine 
glands such as hypothalamus (Rettori et al, 1992), pancreas (Yago et al, 2001) and adrenal 
medulla (Lai et al, 2005). 
  
Nitric oxide in the reproductive system 
Nitric oxide is involved in most processes of human reproduction (Figure 3). There is 
convincing evidence that NO, both ovarian cell-derived and vascular endothelian cell-derived, 
plays an important role in the physiology and biology of the ovary with regard to regulation of 
folliculogenesis and ovulation (Shukovski and Tsafriri, 1994; Zackrisson et al, 1996; 
Ekerhovd et al, 2001). Nitric oxide mediates contractile activity in the Fallopian tube 
(Rosselli et al, 1994; Ekerhovd et al, 1997). It regulates endometrial receptivity, implantation 
and menstruation (Shi et al, 2003; Sun et al, 2003; Mörlin and Hammarström, 2005) and 
promotes embryonal implantation (Zhang et al, 2005). Nitric oxide has been shown to play a 
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role in regulating smooth muscle cell contractility, contributing to uterine quiescence during 
pregnancy (Norman et al, 1997; Ekerhovd et al, 1999). In the human myometrium all three 
isoforms of NOS are present. Their physiological role during pregnancy and labor has been 
studied in detail (Buhimschi et al, 1996). In the uterine body it has been demonstrated that 
these enzymes are up-regulated during pregnancy but down-regulated during labor. Hence, 
NO seems to play an important role for maintaining pregnancy. While NOS enzymes of the 
uterine body decrease towards term, an up-regulation of NOS enzymes takes place within the 
uterine cervix at term before onset of labor. The mechanisms that regulate NOS activity 
during pregnancy are still not known. However, it has been suggested that cytokines may play 
a role (Das et al, 1992; Bry and Hallman, 1993). In the rat uterus, interactions between 
cyclooxygenase, NO and cytokines have been described (Dong and Yallampalli, 1996). 
Similar interactions may exist in the human uterine body. 
 
 
 
Figure 3. Various reproductive processes regulated by nitric oxide. 
 
Nitric oxide also plays an important role in the male reproductive system. In 1990 Ignarro and 
co-workers demonstrated that electrical stimulation for penile erection promoted endogenous 
formation and release of NO. Nitric oxide synthase activity has been localized in penile 
neurons (Burnett et al, 1992) and in the endothelium of penile vasculature and sinusoidal 
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endothelium within the corpora cavernosa (Burnett et al, 1996). It has been shown that the 
NO-cGMP pathway is largely responsible for mediating penile erection (Melis et al, 1996; 
Penson et al, 1996; Zvara et al, 1997). By inhibiting the degradation of cGMP penile erection 
can be achieved. Presence of NOS activity has also been demonstrated in other male 
urogenital organs (Ehren et al, 1994; Burnett et al, 1995). It has been established that the NO-
cGMP pathway is present in testicular cells. This pathway may participate in the regulation of 
testicular function, for instance spermatogenesis (Zini et al, 1996) and steroidogenesis 
(Adams et al, 1994). Nitric oxide also regulates sperm motility (Hellström et al, 1994). In 
addition, LHRH not only triggers the synthesis of gonadotrophins and gonal steroids but also 
participates in regulating mating behaviour in vertebrates (Moss and McCann, 1973; Sakuma 
and Pfaff, 1983). Studies have indicated that NO-induced mating is LHRH mediated (Mani et 
al, 1994). Nitric oxide seems to be regulating both male and female sexual behaviour (Hull et 
al, 1994; Rachman et al, 1996). It has also been shown that oxytocin induces LHRH release 
via NO generation, suggesting that sexual effects of oxytocin are NO mediated (Rettori et al, 
1997). 
 
CERVICAL RIPENING 
 
Normal anatomy and physiology 
The uterus consists of two basic parts: the corpus (uterine body) and the cervix. The most 
caudal part of the cervix, portio cervicis uteri, protrudes into the vagina and is approximately 
2 cm long (Danforth, 1947; Leppert et al, 1986). The entire uterus is composed mainly of 
smooth muscle and extracellular matrix. The cervix, however, consists mainly of connective 
tissue (85-90%), smooth muscle constituting only 10-15% of the tissue (Danforth, 1983). The 
extracellular matrix consists of connective tissue, mainly collagen bundles, type I and III 
(Leppert, 1995; Kelly, 2002). Type IV collagen is also present in smooth muscle cells and 
blood vessel walls (Minamoto et al, 1987). Water, glycosaminoglycans, and proteoglycans are 
important constituents of the extracellular matrix, especially dermatan sulphate, hyaluronic 
acid and heparin sulphate (Golichowski et al, 1980; Leppert, 1995). Fibronectin, laminin and 
elastic fibers are other constituents of the extracellular matrix. Towards term a fundamental 
reorganization of the extracellular matrix occurs, comprising changes in the composition of 
proteoglycan complexes, collagen breakdown and water contents. These biochemical events 
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underly the overt clinical changes in the consistency, dilatation and effacement of the cervix, 
as evaluated by the classical Bishop score. Parturition can be divided into two major phases: 
1) Conditioning (preparatory) phase and 2) irreversible active labor phase (Chwalisz and 
Garfield, 1997). Cervical ripening is an integral part of the conditioning phase of parturition. 
It occurs independently of uterine contractions (Leppert, 1995; Chwalisz and Garfield, 1998). 
It is an active biochemical process similar to an inflammatory reaction, involving infiltration 
of leukocytes, activation of degradative enzymes (MMP, LPS) leading to rearrangement of 
extracellular matrix proteins and glycoproteins (Leppert, 1995; Maul et al, 2003; Sennström 
et al, 2003).  
 
Control 
Progesterone appears to have a dominant role in cervical ripening since antiprogestins are 
effective agents in inducing cervical ripening (Chwalisz, 1998; Neilson, 2004). Treatment 
with antiprogestin has been shown to induce labor at term (Stenlund et al, 1999; Neilson, 
2004). In animals, the progesterone agonist R5020 completely blocked onapristone induced 
cervical ripening, indicating that the process was mediated via the progesterone receptor 
(Chwalisz, 1994; Garfield et al, 2001). However, it has been shown that cervical ripening 
starts long before the decrease in serum progesterone, indicating an additional progesterone-
independent mechanism (Shi et al, 1996). Oestrogen has also been attributed a role in cervical 
ripening since vaginally applied oestrogen has been shown to promote cervical ripening 
(Trumans et al, 1979; Keirse and Van Oppen, 1989) and oestradiol attenuated onapristone-
induced cervical ripening (Chwalisz et al, 1995). In addition, relaxin, an ovarian and placental 
hormone, stimulates cervical ripening (Leppert, 1992). The corticotropin releasing hormone 
(CRH) is also considered to play a role in cervical ripening. This hormone is produced by the 
placenta and myometrium during preganancy (Berkowitz et al, 1996; Challis, 2000). It is 
believed to contribute to the up-regulation of iNOS. It stimulates PG production and is 
thought to act synergistically with oxytocin during labor. Parturition is also associated with an 
increase in different interleukins in the cervix, as well as in the chorio-decidua and the amnion 
(Sennström et al, 2000; Osman et al, 2003; Sakamoto et al, 2004). The levels of IL-8 
correlate with the expression of collagenases (Garcia-Valesco and Aric, 1999) and increase at 
term vaginal delivery (Sennström et al, 1997; Osman et al, 2003). Furthermore, tumor 
necrosis factor alpha (TNF-α) seems to be involved in cervical ripening (Chwalisz, 1994). It is 
produced in decidual and amniotic cells and stimulates COX-2 and subsequent PG formation 
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(Casey et al, 1989; Keelan et al, 2003). These inflammatory events result in vascular 
dilatation and extravasation of leukocytes (Winkler and Rath, 1999), considered as the main 
source for release of collagen degradating matrix metalloproteinases (MMPs), a family of at 
least 17 enzymes (Hulboy et al, 1997) capable of degrading collagen as well as other 
extracellular matrix components. Especially MMP-8 has been found to play a central role in 
this process (Sennström et al, 2003; Aronsson et al, 2005). It has also been suggested that 
MMP-1 and MMP-3 are involved in the ripening process (Sennström et al, 2003).  
 
                  
Role of prostaglandins, cyclooxygenases and NO in cervical ripening 
Prostaglandins, especially PGE2, have for a long time been thought of as key mediators of 
cervical ripening (Kelly, 1994) by causing dilatation of cervical vessels and extravasation of 
leukocytes (Winkler and Rath, 1999). Synthesis of PGs has been described in the amnion, 
decidua, chorion, myometrium, placenta and cervix with the human cervix synthesizing 
primarily PGE2 (Ekman et al, 1983; North et al, 1991; Barcley et al, 1993; Zakar et al, 1996; 
Kayem et al, 2003; Korita et al, 2004). PGE2 is thought to act principally as a vasoactive 
agent. It facilitates infiltration by inflammatory cells and also regulates the release of 
cytokines. It has also been reported to stimulate collagenase activity (Goshowaki et al, 1988). 
PGF2α is known to increase hexosamine, a constituent of glycosaminoglycans, and to increase 
hyaluronic synthetase activity (Rath et al, 1987). In the uterus the contractile effect of PGs is 
well known. However, their role in the cervical ripening process has been questioned, as this 
process is independent of uterine contractions. COX is the rate-limiting enzyme in the 
biosynthesis of PGs. In addition to the well characterized constitutive form of COX (COX-1) 
(deWitt, 1991), an inducible isoform of COX (COX-2) is found in endothelial cells (Maier et 
al, 1990), fibroblasts (Raz et al, 1988) and macrophages (Fu et al, 1990; Masferrer et al, 
1990; 1992). COX-2 is typically undetectable in most tissues under normal physiological 
conditions but can be expressed at high levels following stimulation. A recent study has 
shown that there is an increase in cervical COX-1 and COX-2 at parturition (Stjernholm-
Vladic et al, 2004). Moreover, from several studies conclusions have been made that PGs can 
stimulate the release of NO (Maul et al, 2003). The role of 15-OH prostaglandin 
dehydrogenase (PGDH), an enzyme responsible for the metabolism of PG to inactive 
metabolites, in preterm labor (PTL) is not known. Studies have shown that PGDH activity is 
lower in the chorion at PTL (van Meir et al, 1997) and that the activity is decreased by 
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antiprogestines and cortisol (Patel et al, 1999). Thus, decreasing PGDH activity at term may 
have a role in cervical ripening. 
 
Nitric oxide is involved in regulating many factors in the inflammatory process of cervical 
ripening. All three isoforms of NOS are present in the human uterine cervix (nNOS, iNOS, 
eNOS) (Tschugguel et al, 1999; Ledingham et al, 2000; Bao et al, 2001). Inducible NOS has 
been localized in the epithelial cells and stromal spindle cells (Tschugguel et al, 1999) and 
has been demonstrated by immunostaining in uterine cervix at term (Ekerhovd et al, 2000). 
Furthermore, iNOS has been shown to be up-regulated in human uterine cervix during 
delivery (Tschugguel et al, 1999; Ledingham et al, 2000). The metabolites of NO in cervical 
fluid are increased at term compared to preterm (Väisänen-Tommiska et al, 2003). The iNOS 
isoform can be induced by cytokines, TNF-α, interferon-λ or endotoxins (lipopolysaccharides) 
in a calcium-independent manner as has been described earlier. Nitric oxide may exert its 
effect through stimulation of endogenous PG synthesis through COX-activation (Salvemini et 
al, 1993) or through stimulation of at least one MMP, MMP-1 (Yoshida et al, 2001). Animal 
studies, though, have shown that NO has an effect on several MMPs in other human and 
animal tissues (Murrell et al, 1995; Trachtman et al, 1996; Sasaki et al, 1998).  
 
An alteration in the glycosaminoglycan composition of the cervix occurs during late 
pregnancy, which may be important in the ripening process. The amount of hyaluronic acid 
present in the cervix increases at term. These changes bring about an alteration in the binding 
affinity to collagen thus altering the tissue hydration and hence cervical extensibility 
(Rechberger et al, 1996). Nitric oxide suppresses proteoglycan synthesis (Hauselmann et al, 
1998). In addition, NO may also promote apoptosis which has been described in smooth 
muscle cells (Romero et al, 1990) and fibroblasts (Leppert, 1998) during cervical ripening. 
Several lines of evidence from studies of other tissues suggest that this process is stimulated 
by NO (Nicotera et al, 1997; Brüne et al, 1998). Finally, cervix constitutes to 10-15% of 
smooth muscle cells, the role of which has only to some extent been examined. Relaxing 
effects of cervical smooth muscle following administration of NO donors have been 
demonstrated in vitro in cervical tissue specimens from early pregnant as well as term women 
(Ekerhovd et al, 1998; Ekerhovd et al, 2000). 
 
Taken together, NO has been proposed to be the final mediator of cervical ripening, according 
to Chwalisz and Garfield (Figure 4).  
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Figure 4. Model of cervical ripening. ECM=extracellular matrix. 
 
Cervical ripening and induction of labor 
Induction of labor can be defined as an intervention designed to artificially initiate uterine 
contractions leading to progressive dilatation and effacement of the cervix and birth of the 
infant. (Royal College of Obstetricians and Gynaecologists (RCOG), Induction of Labour, 
Guideline Nr 9). This includes both women with intact membranes and women with 
spontaneous rupture of membranes who are not in labor. As with any other intervention, 
induction of labor may have unwanted effects, but is indicated when it is agreed that the 
mother or the fetus will benefit from a higher probability of a healthy outcome than if birth is 
delayed. Naturally, the process of induction of labor should only be considered when vaginal 
delivery is felt to be the appropriate route of delivery. Induction of labor is a common 
procedure: about 20% of pregnant women will have labor induced for a variety of reasons 
according to RCOG. In Sweden, however, the induction rate is lower, approximately 10% 
according to local statistics. Induction does not usually involve just a single intervention but a 
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complex set of interventions and, as such, presents challenges for both clinicians and mothers. 
Figure 5 shows a schematic model of different methods of induction according to membrane 
and cervical status.  
Cervical status can predict the success of induction and duration of labor (Jackson and Regan, 
1997). The most common method for assessment of cervical status is by using the modified 
Bishop score (Bishop, 1964; Calder et al, 1977; Fuentes and Williams, 1995; Laube, 1997). 
This score is based on five factors: cervical dilatation, effacement, station, consistency and 
position. Each factor is graded from 0-2 giving a maximum score of 10 points. A total score 
of 4-8 is according to the literature regarded as an indication of a ripe cervix (RCOG, 2001). 
Amniotomy is feasible for induction of labor when the score is ≥6. The optimal method for 
inducing labor should be efficient but should not cause uterine hyperstimulation or other 
major side effects. If the membranes are ruptured and cervix is considered ripe, the method of 
choice is stimulation by oxytocin infusion. Oxytocin can be administered intravenously to 
cause uterine contractions and dilatation of cervix. The effect of oxytocin depends more on 
the number of receptors on the uterine myometrial cells than on the actual local hormone 
concentration. If the cervix is found to be unripe both oxytocin and PGs can be used. 
However, according to RCOG PGs are recommended for preinduction cervical ripening for 
better labor outcome. When the membranes are intact and cervix is ripe it is most common to 
induce labor with either amniotomy or oxytocin, or the combination of both. If the cervix is 
unripe different methods can be used for inducing cervical ripening before onset of 
contractions. Prostaglandins can be administered orally, sublingually, rectally, vaginally or 
intracervically. Numerous studies have been performed to find the optimal dose, drug and 
administration form. However, PGs are associated with side effects, such as uterine 
hyperstimulation, nausea and abdominal pain (Keirse, 1994). The most common PGs used 
today for cervical ripening are PGE2- and PGE1- analogues. Bygdeman and co-workers have 
also concluded that during early pregnacy the combination of mifepristone and PG is effective 
for termination of pregnancy (Bygdeman and Swahn, 1989). In the second trimester 
pretreatment with the antiprogestin mifepristone will significantly reduce the duration of 
labor, dose of PG, and the frequency of side effects (Bygdeman et al, 2000). Beside 
antiprogestin effects mifepristone also has anti-glucocorticoid and estrogen-realated 
properties (Olive, 2002). Mifepristone induces uterine contractions by blocking progesterone 
and by inducing COX activity (Hapangama et al, 2002), but it is not known how it promotes 
cervical ripening. Furthermore, Stenlund and co-workers have performed a study using 
mifepristone for labor induction. Thirty-six postterm pregnant women with an unripe cervix 
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were given either 400 mg mifepristone (n=24) or placebo (n=12). During the first 48 hours 
following treatment, 79% of the women treated with mifepristone compared to 16% of the 
women who received placebo tablets went into labor (Stenlund et al, 1999). Neilson has later 
confirmed that mifepristone can be used for termination of late pregnancy (Neilson, 2004). 
Mechanical treatment with an intracervical Foley catheter to achieve cervical dilatation prior 
to labor induction represents an alternative to medical treatment. The technique was described 
in 1967 (Embrey and Mollison, 1967). The use of the transcervical Foley catheter has been 
demonstrated to be both safe and effective for preinduction cervical ripening (Leiberman et 
al, 1977; James et al, 1994; Levy et al, 2004). However, because of its mechanical effects on 
the cervix one must consider possible damaging effects on the cervix and the risk of 
premature labor in future pregnancies (Gelber and Sciscione, 2006). After the Foley catheter 
is removed patients generally require other methods for further labor induction. In cases 
medical treatment for cervical ripening has failed the use of a balloon catheter could be an 
alternative to caesarean section.  
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Figure 5. Methods of induction of labor.  
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Nitric oxide donors for cervical ripening   
It is well established that NO donors have a cervical ripening effect (Chwalisz et al, 1994; 
Chwalisz and Garfield, 1997; Shi et al, 2000). Sodium nitroprusside (SNP), isosorbide 
mononitrate (IMN) and glyceryl trinitrate (GTN) are NO donors that have been administered 
vaginally in the first and second trimester before termination of pregnancy, and have shown to 
have ripening effects on the cervix (Thomson et al, 1997; Facchinetti et al, 2000; Ledingham 
et al, 2001; Eppel et al, 2005). The mechanism of action of NO donors has been addressed by 
a number of in vivo and in vitro studies. A complex interaction between NO and PGs, COX-
enzymes, cytokines, glycoproteoglycans, MMPs, apoptosis, as well as smooth muscle cells 
seems to exist. The advantage of using NO donors for cervical ripening is its relaxing effect 
on uterine contractions, thus probably decreasing the risk of fetal side effects. Since 2000 
several clinical studies have been performed using NO donors for cervical ripening at term 
pregnancy. Before NO donors can be generally applied in clinical practice it is of importance 
to identify possible maternal and fetal side effects. In one study maternal blood pressure and 
pulse rate were significantly affected following treatment with IMN, but no side effects of 
clinical importance were registered (Nicoll et al, 2001). Table 2 summarizes the results from 
clinical studies on NO donors for cervical ripening and labor induction in pregnant women at 
term. No difference in the rate of caesarean section was seen. However, the ripening effect of 
PGs seems to be more efficient than NO donors according to Bishop score and cervical 
distensibilty measured by cervical tonometer (Thomson et al, 1998). Of importance is the fact 
that no women treated with NO donors even after up to 3 consecutive doses suffered from 
uterine hypertonus. Thus, the possibility to induce labor in an outpatient setting by means of 
NO donors seems evident. Another aspect is the fact that clinical studies have shown that NO 
donors not only ripen the cervix but also seem to induce labor (Chanrachakul et al, 2000a; 
2000b; 2002). According to these studies, 27-39% of the women went into labor within 24 
hours following vaginal administration of NO donors. This could indicate that a vaginally 
applied NO donor initiates a cascade of events that not only leads to ripening of the cervix but 
also effective labor.   
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Author N Medical 
agent  
&  dose 
Comparison 
agent 
Exposure  
time 
(hours) 
 
Cervical 
Ripening 
Chanrachakul 
et al 
2000 
110 GTN 
0.5mg 
Dinoprost 
3mg 
6 GTN<Dinoprost 
CS 35% vs 35% 
Nicoll et al 
2001 
 
 
 
36 IMN 
20mg 
 
IMN 
40mg 
Vaginal 
examination 
 
Vaginal 
examination 
6 
 
 
6 
 
IMN=vaginal 
examination 
CS 46% vs 33% 
IMN=vaginal 
examination 
CS 18% vs 33% 
Chanrachakul 
et al 
2002 
107 IMN 
40mg 
Three doses 
Misoprostol 
0.05mg 
Three doses 
6  IMN<Misoprostol 
CS 36% vs 31% 
Sharma et al 
2005 
65 GTN 
0.5mg 
GTN 
0.5mg 
Misoprostol 
0.05mg 
Dinoprost 
3 mg 
6 
 
6 
GTN<Misoprostol 
CS 43% vs 48% 
GTN<Dinoprost 
CS 43% vs 53% 
Osman et al 
2006 
400 IMN 
40mg,  
Two doses 
 
PGE2  
2mg, 
Two doses 
12 IMN<PGE2 
CS 33% vs 31% 
Wölfler et al 
2006 
120 IMN 
40mg + 
Dinoprost 
3 mg 
2doses/day 
up to 2 days 
Placebo + 
Dinoprost 
3mg 
 
2doses/day 
up 
to 2 days 
6 IMN+Dinoprost= 
Placebo+Dinoprost 
CS 33% vs 25% 
Nunes et al 
2006 
 
196 GTN 
0.5mg + 
Dinoprostone 
2 mg 
Placebo +  
Dinoprostone
2mg 
6 IMN+Dinoprost= 
Placebo+Dinoprost 
IMN group shorter 
time to delivery 
CS 32% vs 34% 
 
Table 2. Randomized controlled trials on NO donors for cervical ripening at term. IMN: 
isosorbide mononitrate; GTN: glyceryl trinitrate; SNP: sodium nitroprusside; CS: 
caesarean section, N: number of women. 
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THE PLACENTA 
 
Normal anatomy  
After conception the development of embryo and placenta is divided into several events from 
mitotic divisions as blastomeres to morula after 3 days, after 4 days to blastocyst consisting of 
inner cell mass (embryoblast) and outer ring of trophoblast cells. The outer layer proliferates 
and differentiates to cytotrophoblasts and syncytiotrophoblasts. The hypoblast is then formed 
from inner cell mass later giving rise to a loosely arranged tissue named the extraembryonic 
mesoderm. Trophoblasts and the extraembryotic mesoderm later form the chorion. At its final 
stage the human placenta consists of two components: 1) The chorion, including the 
syncytiotrophoblast, the cytotrophoblast and the extraembryotic mesoderm, and 2) the 
allantois, containing three umbilical vessels (2 arteries and 1 vein). The amniotic cavity takes 
form at the embryonic pole, a layer from the inner cell mass which differentiates into a thin 
membrane that separates the new cavity (amnion) from the cytotrophoblasts. The fetal 
trophoblast invades the endometrium, brakes down endometrial blood vessels into lacunae 
and forms villi. Thus, the placenta becomes a materno-fetal unit with the fetal portion formed 
by the chorion (chorionic plate) and the maternal portion formed by the decidua basalis (basal 
plate). Chorionic villi begin to develop with extensions of cytotrophoblasts, covered with 
syncytiotrophoblasts, growing out into the lacunae, called primary stem villi. The villi 
undergo further development to secondary (intermediate) and tertiary (terminal) villi, the last 
ones constituting of anchoring villi, which reach the maternal endometrium. After 
implantation all but the deepest layer of the endometrium proliferates. These proliferating 
cells constitute the decidua. Stromal cells under the influence of invading trophoblasts, 
differentiate into large, rounded, glycogenfilled decidual cells. There are three regions of the 
decidua: 1) decidua basalis, underlying the implantation site, 2) the decidua capsularis, a thin 
portion between the implantation site and the uterine lumen surrounding the chorion, and 3) 
the decidua parietalis, including the remaining endometrium. As the embryo grows, the 
amnion rapidly expands until the chorionic cavity is obliterated and its surrounding decidua 
capsularis eventually fuses with the decidua parietalis, thereby obliterating the uterine cavity 
by the third month.  
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Figure 6. Placenta to the left and a placental stem villus to the right. 
 
Normal physiology 
Circulation through the embryo and the villi starts at about day 21 with the intervillous space 
as the site of exchange of nutrients and waste products between the maternal and fetal 
circulatory system. Fetal and maternal blood circulations do not mix since they are separated 
by the placental barrier which is derived from fetal tissue. The placenta has three main 
functions: 1) metabolism, 2) transport of substances and 3) endocrine secretion. 
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Metabolism. During early pregnancy the placenta synthesizes glycogen, cholesterol and fatty 
acids, which serve as sources of nutrients and energy for the growing embryo. 
 
Transport. The placenta has a very large surface area which facilitates exchange of 
substances. At 28 weeks of gestation the surface area is 5 square meters, and at term almost 
11 square meters. Approximately 5-10% of this surface area is extremely thin, measuring only 
a few microns. Deoxygenated fetal blood enters the placenta via two umbilical arteries and 
runs through capillaries in the villi, where gases and metabolites are exchanged across the 
placental barrier with maternal blood supplied by spiral endometrial arteries. Oxygenated fetal 
blood returns from the placenta via the umbilical vein. Oxygen, water, carbon dioxide, 
hormones, vitamins and antibodies can all cross the placental barrier. The exchange of gases 
occurs via diffusion. The placenta is also highly permeable to glucose, but less permeable to 
disaccharides. Amino acids are transported through specific receptors. Proteins are transferred 
slowly through the placenta, mainly via pinocytosis. The transfer of maternal antibodies, 
mainly IgG, is important in providing passive immunity to the infant. Another maternal 
protein, transferrin, carries iron to the placental surface from where it is actively transported 
to fetal tissues. Steroid hormones easily cross the placental barrier, while protein hormones 
are not as easily transported across the barrier. Placenta is also permeable to alcohol and other 
drugs and to some viruses.  
 
Endocrine secretion. The syncytiotrophoblast is an important endocrine organ for 
maintaining pregnancy. It produces both proteins and steroid hormones. The major placental 
hormones are human chorionic gonadotropin (hCG), estrogens, progesterone, human 
placental lactogen (hPL), human chorionic somatomammotropin (hCS), human placental 
growth hormone, human chorionic thyrotropin (hCT), human chorionic adrenocorticotropin 
(hACTH), insulin-like growth factors, endothelial growth factors and relaxin. In addition, the 
placenta produces dozens of proteins that have been identified immunologically but whose 
function is poorly understood.  
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Placental detachment 
Labor can be divided into three stages: first, second and third stage of labor. The first stage of 
labor refers to the interval between the onset of regular contractions and full dilatation of the 
cervix.  The second stage of labor starts at full cervical dilatation and ends with the delivery 
of the infant. The third stage of labor is the interval between the delivery of the infant and the 
delivery of the placenta. This interval has a mean duration of 6.8 minutes (Combs, 1991).  
There is a six-fold increase in the risk for postpartum hemorrhage (PPH) if the third stage of 
labor is prolonged to over 30 minutes (Combs, 1991).  Little is known about the physiology 
and pathophysiology of the third stage of labor. Historically, there have been given different 
explanations to why placenta detaches. Brandt (Brandt, 1933) suggested it was detached due 
to retroplacentar hematoma, while Dieckmann and co-workers (Dieckmann et al, 1947) 
stressed the importance of slow delivery of the fetus so that the uterine wall was given time to 
contract and retract. Ultrasound imaging of the third stage of labor led Herman and co-
workers (1993) to divide the third stage of labor into four phases: the latent phase, the 
contraction phase, the detachment phase, and the expulsion phase. In the latent phase, which 
immediately follows the delivery of the infant, all of the myometrium except that behind the 
placenta contracts. In the contraction phase this retro-placental myometrium contracts.  This 
leads to the detachment phase where the non-elastic placenta is torn from the decidua. The 
placenta is expelled from the uterus due to uterine contractions in the expulsion phase 
(Herman et al, 1993; Weeks, 2001). 
 
Etiologies behind retained placenta. Retained placenta, a major cause of PPH, is a failure of 
the placenta to separate from the uterus.  Retained placenta occurs in 2.0-3.3% of all vaginal 
deliveries and is the cause of 6-7% of all cases of PPH (Combs and Laros, 1991; Dombrowski 
et al, 1995). The incidence increases with decreasing gestational length (Combs, 1991; 
Dombrowski, 1995). The pathophysiology behind retained placenta is still unknown and little 
research has been carried out to understand its etiology. Dynamic ultrasonographic imaging of 
the third stage of labor has demonstrated that retro-placental myometrial contractions are 
necessary for placental detachment and that lack of retro-placental contractions resulted in 
retained placenta (Herman et al, 1993). Recently, Farley and co-workers demonstrated that 
human chorionic villi are able to contract and relax along their longitudinal axes and that this 
ability is under the control of NO (Farley et al, 2004). As early as 1906 smooth muscle-like 
spindle-shaped cells were observed in the chorionic plate of the term human placenta. Then in 
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1916 Iizuka confirmed that the spindle-shaped cells were smooth muscle cells (Krantz and 
Parker, 1963). Also noted at that time was that the muscle cells were denser at the center of 
the placenta where the umbilical cord is inserted and more sparse toward the periphery. In 
1922 Naujoks proposed the hypothesis that the human placenta is capable of contraction. 
Krantz and Arey later demonstrated that these cells in the placenta have all the morphological 
characteristics of smooth muscle cells (Kranz and Parker, 1963). More recently, Graf and co-
workers confirmed the presence of myofibroblasts in stem villi by demonstrating the 
immunolocalization of vimentin, desmin, -actin, -actin, and myosin in these cells (Graf et 
al, 1994). They also suggested that the change in villus length is an active process, something 
that later was confirmed by Farley (2004). This mechanism, that anchoring villi have 
contractile properties was suggested to underlie placental separation.  
 
 
Figure 7. Schematic drawing of anchoring villi attached to the basal plate in the decidua. 
These anchoring villi have relaxing properties, which can be stimulated by NO. 
 
The placental function is an important determinant of the onset of labor, and therefore it is 
also likely that placenta does not detach during pregnancy and first stage of labor due to an 
inhibitory factor.  Potential candidates for this inhibitory factor have been suggested to be 
progesterone and/or NO (Garfield et al, 1998). Pathologically adherent placenta is caused by 
abnormal placentation and is generally classified into two groups depending on how far into 
the myometrium the chorionic villi have penetrated.  Placenta accreta incompasses superficial 
penetration of the villi into the myometrium, and placenta percreta includes deeper 
penetration, in some cases through to the serosa, which may lead to uterine rupture. Risk 
factors for retained placenta are in descending order of significance:  a history of retained 
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placenta, previous uterine surgery, preterm delivery, maternal age >35 years, placental weight 
less than 601 g, pethidine (an opioid analgesic) used during labor, labor induction, and parity 
of more than five (Soltan and Khashoggi, 1997). 
 
Treatment of retained placenta 
There are several different techniques for the management of a retained placenta (Figure 8).  
The techniques vary in several aspects, from time of intervention to method of treatment 
(pharmaceutical, invasive). Active management of the third stage of labor may result in a 
reduction in blood loss as well as a decrease in the average length of the third stage of labor. 
However, there is inconsistency in the results from studies concerning active management and 
its effect on retained placenta (Prendiville et al, 2000). The treatments summarized in this 
section are manual removal of placenta (MROP), and the use of various medications: 
oxytocin, PGs and nitroglycerin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Different methods for management of retained placenta.  
MROP: manual removal of placenta. 
 
Manual Removal of Placenta 
Manual removal of placenta (MROP) is the traditional management of retained placenta. It 
requires some form of hospital setting.  This involves the use of anaesthetic (either regional or 
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general) and possibly the use of a further uterine relaxant to facilitate the manual removal of 
the placenta. Apart from the inherent risks associated with anaesthesia, MROP increases the 
risk of hemorrhage, infection due to the introduction of vaginal bacteria, rupture of the uterus, 
and trauma to the cervix or vagina (Carroli, 1991).  General anaesthesia also carries the 
psychological impact of separating the mother from her family and newborn.  A method for 
management of retained placenta that would reduce the need for manual removal in a hospital 
setting would be of major benefit to women worldwide. 
 
Oxytocin 
Oxytocin is currently only used in obstetrics for labor induction and stimulation of 
myometrial contractions. It has to be administered parenterally due to its short half-life and 
susceptibility to proteolytic cleavage (Mycek, 2000).  Oxytocin may act as a labor promoting 
substance in multiple ways. It promotes myometrial contractility by increasing free 
intracellular calcium (Brucker, 2001). Furthermore, oxytocin exerts a stimulatory effect on the 
release of PGs, leukotrienes, cytokines, and NO (Ticconi et al, 2004), thereby possibly and 
indirectly contributing to degradation of extracellular matrix within both the uterine body and 
the cervix. The use of oxytocin has come under widespread debate over the years due to 
mixed results in several studies. Studies have also shown that the mean duration for third 
stage of labor is approximately 6 minutes, and that this interval is not shortened by 
administration of oxytocin (Combs and Laros, 1991; Herman et al, 1993). It has been 
suggested that results may be so varied due to the differences in dosage and method of 
administration (Carroli, 2001). The methods include intramuscular, intravenous or 
intraumbilical injections. The latter method involves direct delivery of an oxytocic agent via 
umbilical injection to the retro-placental myometrium, which is the area of uterine muscle 
failing to contract. The efficacy of this method has been questioned (Makkonen et al, 1995).  
One study, however, resulted in a success rate of 93% in delivering retained placentas using 
this method (Chauhan, 2000). A Cochrane review, analysing twelve trials, concluded that the 
umbilical vein injection of oxytocin and saline solution appeared to be effective in the 
management of retained placenta, but that further research was needed (Carroli, 2001).  
 
Prostaglandins 
Like oxytocin PGs increase intracellular free calcium, thus promoting uterine contractions 
(Brucker, 2001). The advantage of PGs is that they can be administered in different forms, 
either vaginally, rectally, orally, intravenously or intraumbilically. Misoprostol (a stable 
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analogue of PGE1), sulprostone (a PGE2 analogue), as well as carpoprost (PGF2α) have been 
used in studies for the management of retained placenta (Bider et al, 1995; Li et al, 2001; van 
Beekhuizen et al, 2005). Intravenous administration of 250 μg of sulprostone for thirty 
minutes in women with retained placenta reduced the need for MROP by 49% (van 
Beekhuizen et al, 2005). Bider and co-workers showed that intraumbilical venous 
administration of PGF2α was an effective treatment of retained placenta with negligible side 
effects. Li and colleagues (2001) found in an uncontrolled study that rectal administration of 
800 μg of misoprostol for treatment of retained placenta resulted in a 100% successful rate. 
Furthermore, rectally administered misoprostol compared to placebo has been shown to be 
effective (Darney, 2001; El-Refaey, 2002; O´Brien et al, 2002; Shannon and Winikoff, 2002). 
Ng and co-workers found that there were significantly fewer retained placentas following the 
use of oral misoprostol as a prophylactic agent compared to syntometrine (oxytocin plus 
ergometrine) (Ng et al, 2001). However, according to an analysis by WHO intravenous or 
intramuscular oxytocin is preferable over oral misoprostol in the active management of the 
third stage of labor (Gülmezoglu et al, 2001). This conclusion could be questionable, as WHO 
based it on a 1% difference in results (the incidence of major PPH during treatment with 
misoprostol and oxytocin were 4% vs 3%, respectively).   
 
Nitric oxide donors 
Several reports have indicated that intravenously administered nitroglycerin is effective for 
successful delivery of retained placenta (DeSimone, 1990; Dufour et al, 1997; Axemo et al, 
1998; Chedraui and Insuasti, 2003). Nitroglycerin is a well known NO donor. In vitro, NO 
donors, including nitroglycerin, induce immediate relaxation of the term pregnant 
myometrium as well as the uterine cervix (Buhimschi et al, 1995; Norman et al, 1997; Axemo 
et al, 1998; Ekerhovd et al, 2000). Nitroglycerin administered intravenously causes uterine 
relaxation within 45-60 seconds. The relaxation normally lasts for two minutes (Axemo et al, 
1998). If administered sublingually plasma concentration reaches its maximum within five 
minutes with a half-life of about three minutes. Nitroglycerin is known to affect blood 
pressure because of its vasodilating properties, but no study on nitroglycerin has reported 
serious decrease in blood pressure or uncontrolled bleeding after treatment of retained 
placenta with intravenous nitroglycerin. Only one case report has previously been published 
where sublingual administration of an NO donor, isosorbide dinitrate, was successfully used 
for manual removal of retained placenta (Okawa et al, 2002). In a recently published study it 
was demonstrated that oxytocin exerts an overall stimulating effect on NO release by fetal 
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membranes at term and that this stimulating effect is more marked after labor than before 
labor (Ticconi et al, 2004). An interaction between oxytocin and NO could play a role in 
promoting placental separation.  
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AIMS OF THE STUDY 
 
 
The overall aim of this study was to determine in clinical and experimental studies whether 
NO donors have an influence on cervical ripening and labor induction at term or postterm 
pregnancy, and whether nitroglycerin in a sequential treatment with oxytocin has an effect on 
the management of retained placenta. In this context the following questions have been 
addressed: 
 
 
 Are NO donors effective in inducing cervical ripening when administered 
intravaginally at term? 
 
 
 Do NO donors, administered intravaginally, have an effect on labor induction? 
 
 
 Do NO donors cause maternal and fetal side effects? 
 
 
 Is it safe to administer NO donors for labor induction in an outpatient setting? 
 
 
 Are cervical COX enzymes affected by locally administered NO donors? 
 
 
 Is the sequential combination of oxytocin and nitroglycerin for management of 
retained placenta effective and safe? 
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SUBJECTS AND METHODS 
 
The women (N = 308) included in the present thesis were carefully informed about the 
purpose and nature of the studies before giving their consent to participate. Women between 
19 and 43 years of age who were not on any medication were asked to participate. All women 
were in late pregnancy (papers I-III) or had just delivered an infant (paper IV) and none had 
suffered from any pregnancy complication. All studies were approved by the local Human 
Ethics Committee. 
 
Paper I – A clinical randomized controlled study 
In this study 60 patients were included (Figure 9). The primary purpose of the study was to 
evaluate the ripening effect of vaginally administered IMN to term pregnant women by 
measuring intracervical distensibility. Secondarily, possible maternal or fetal adverse effects 
were examined. The women were all scheduled for elective caesarean section at term due to 
breech presentation or for psychological reason. Inclusion criteria were nulliparity, gestational 
age of at least 37 weeks, uncomplicated singleton pregnancy, normal CTG, normal umbilical 
Doppler indices and immature cervical status (Bishop score <6 and cervical length ≥30 mm). 
Randomization was performed by means of numbered, sealed envelopes prepared with 
random-number tablets. Both the IMN (two 20mg tablets of Ismo®, Boehringer Mannheim, 
Mannheim, Germany) and the two placebo tablets were of similar design and were placed into 
the posterior vaginal fornix by a research nurse who was unaware of the agent administered. 
Transvaginal ultrasound of the uterine cervix was conducted for measurement of cervical 
length. Ultrasonography was performed by an obstetrician, who was unaware of the agent 
administered. Before being transported to the operating theatre, the women were asked to 
complete a symptom questionnaire concerning following symptoms: headache, hot flushes, 
palpitations, dizziness, abdominal pain, pelvic pain and nausea. 
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0 min:      CTG, cervical status,  
                Maternal blood pressure 
                Maternal pulse  
                Umbilical resistance index (RI) 
                Umbilical pulsatility index (PI) 
 
                                                                                                       
 
60 min: CTG 
 
120 min: CTG 
 
180 min: Maternal blood pressure 
                Maternal pulse 
                Umbilical PI 
                Umbilical RI 
                 
210 min: CTG 
                Maternal side effects according to VAS-scales 
 
240-270 min: Cervical distensibility measured by cervical tonometer 
 
250-280 min: Apgar score 
                       pH in the umbilical artery 
                       Maternal blood loss 
 
Figure 9. Flow chart showing the procedure from randomization to delivery by 
caesarean section. 
 
Randomization 
      60 women 
          30 women 
          Placebo 
          vaginally 
      30 women 
       40 mg Ismo 
       vaginally 
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At the operating theatre regional anaesthesia was given and the patient placed into lithotomy 
position. Cervical distensibility was measured by a cervical tonometer (Figure 10). The peak 
force (in Newton) required to dilate the cervix from 5 to 10 mm with a cervical dilatator 
connected to the cervical tonometer was registered. Caesarean section was then performed 
according to routine praxis and blood loss was recorded as well as pH in the umbilical artery 
and Apgar scores at 1, 5 and 10 minutes.  
 
 
 
Figure 10. A cervical tonometer used for measuring cervical distensibility. Cumulative 
force (Newton) to dilate the uterine cervix to 10 mm was registered by means of dilators 
with a diameter of 5 to 10 mm connected to the tonometer.     
 
 
Statistical analysis  
A sample size of 60 women in two groups, estimated by Altman nomogram (a graphic 
method to calculate sample size and power), were calculated to yield 80% power at the 5% 
significance level when assuming 0.75 as a standardized difference in the cumulative force to 
dilate the cervix. Standardized difference is based on the ratio of the difference of interest to 
the standard deviation of the observations. This means that the larger the ratio is the smaller 
sample size is required. For comparison between groups Mann-Whitney nonparametric  
U- test was used for continuous variables. All tests were two-tailed and conducted at a 5% 
significance level. 
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Paper II – A double-blind randomized controlled clinical trial. 
The main aim of the study was to investigate the efficacy of 40 mg of IMN administered 
vaginally for labor induction in an outpatient setting and to evaluate the safety with the 
treatment. The study was conducted at Sahlgrenska University Hospital, Sweden and Borås 
Hospital, Sweden. The women had all come to routine postterm control and were asked to 
participate if the following inclusion criteria were met: Uncomplicated singleton pregnancy, 
cephalic presentation, gestational age of at least 42 weeks, Bishop score <6, normal amniotic 
fluid index >5cm, reactive fetal heart pattern, and intact membranes. Examination of the 
cervix included an assessment of cervical status according to Bishop score and closed cervical 
length performed by transvaginal ultrasonography. Two hundred women fulfilled the 
inclusion criteria and agreed to participate (Figure 11). They were randomized to receive 
either 40 mg (two 20 mg tablets) of IMN or 2 placebo tablets of a similar design. The tablets 
were inserted into the posterior vaginal fornix by an obstetrician. Primary outcome was start 
of labor while secondary outcomes were cervical ripening and fetal and maternal side effects. 
Neither the woman nor the obstetrician knew which agent was being administered. However, 
both the participating women and the obstetrician who administered the agent, due to possible 
side effects of the NO donor, could guess which agent had been given.  
  
 
Figure 11. Flow chart of labor induction. IMN=isosorbide mononitrate. 
 
Before returning home each woman was given an appointment for the next day and asked to 
complete a symptom questionnaire about side effects (headache, hot flushes, palpitations, 
        Bishop score<6 
≥42 weeks 
Randomization: 
           Placebo (n=100)  
           IMN (n=100) 
            
             In labor 
   
           Not in labor 
Unripe cervix: 
PGE2 
Ripe cervix: 
Amniotomy 
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dizziness, nausea, and abdominal pain) during the priming interval. To assess the intensity of 
symptoms, a visual analogue scale graded from 0 (no symptoms) to 10 (symptom of 
maximum intensity) was used. If onset of labor occurred before the next day, the women were 
instructed to contact the labor and delivery unit. Onset of labor was defined as regular painful 
contractions (with or without rupture of membranes) combined with cervical length <1cm and 
cervical opening ≥3cm. If regular contractions had not been established within the next day, 
cardiotocography was performed and the cervix was assessed. Labor was induced according 
to the local protocol. Women with a Bishop score ≥6 underwent amniotomy. If the Bishop 
score was <6 or if amniotomy was not feasible, 1 mg of PGE2 was administered vaginally for 
further cervical ripening.  
 
Statistical analysis  
According to audits in our labor units approximately 5-10 out of 100 postterm women would 
go into labor within 24 hours. Previous studies have indicated that vaginal treatment with 
IMN results in labor among 27-39% women within 24 hours. However, these positive results 
are less likely to be achieved among postterm women, and therefore, the expected number of 
women in labor was calculated to be 20-25.  A power of 80% at the 5% significance level was 
reached if 22 out of 100 women went into labor within 24 hours compared to 7 out of 100 
women in the placebo group. Thus, a total number of 200 women were included in the study. 
Fisher exact test was used for assessment of the efficacy of IMN for induction of labor. 
Changes in Bishop score and cervical length were analyzed using two sample t-test, while 
Mann-Whitney U-test was used for assessment of maternal side effects. All categorical 
outcomes in the two groups were compared using Fisher exact test. Logistic regression was 
used to assess the effect of IMN, parity, baseline cervical length, and baseline Bishop score on 
spontaneous labor outcome. All significance tests were two tailed. A p <0.05 was considered 
to be statistically significant.  
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Paper III – An experimental randomized study 
The aim of this study was to examine the relationship between NO and the two enzymes 
COX-1 and COX-2 in the cervical ripening process. Previous studies have demonstrated that 
COX-enzymes are present within the cervix at term pregnancy (Stjernholm-Vladic et al, 
2004). The purpose of this investigation was to evaluate the effect of IMN on cervical COX-
expression and to localize these enzymes within the cervical tissue. The techniques used for 
analysis were immunoblotting and immunohistochemistry (IHC). Twenty-four women 
scheduled for elective caesarean section were recruited to the study. Inclusion criteria were at 
least 37 weeks of gestation, cervical Bishop score <6, singleton pregnancy, no former vaginal 
delivery and uncomplicated pregnancy. All women included were 1–4 days before caesarean 
section informed of the nature and scope of the study, as well as the potential side effects of 
IMN. The women were randomized to receive either 40 mg of IMN (Ismo®, 2 tablets á 20 
mg, Boehringer-Mannheim, Mannheim, Germany) or 2 placebo tablets of similar design 
administered intravaginally in the posterior fornix by an obstetrician 4 hours prior to elective 
caesarean section. After regional anaesthesia, the women were placed in the lithotomy 
position. Cervical tissue specimens were obtained transvaginally from the anterior lip of the 
cervix by use of a 14 gauge Tru-Cut biopsy needle (Allegiance Healthcare Corporation, 
McGore Park, IL, USA) (Figure 12). Three cylindrical biopsies of approximately 1.5 x 15 mm 
size (wet weight 25–40 mg) were obtained from each woman. Tissue specimens were 
immediately transferred to liquid nitrogen and frozen at -70ºC until analysis.  
 
 
Figure 12. A Tru-cut® biopsy needle. 
 
Immunoblotting 
Immunoblotting is an immunologic method used for detecting or quantifying immunoreactive 
substances. This process involves the characterization of a factor based on the molecular 
weight and ability of antibody to bind to it. It is used to identify and characterize antigens 
 36    
from a complex mixture. The antigen samples are resolved by separation in an analytical gel 
such as sodium dodecyl sulphate, peptide mapping gels or isoelectric focusing gels. The 
resolved molecules are transferred electrophoretically to a nitrocellulose membrane in a 
blotting tank. The blot is then treated with a monoclonal or polyclonal antibody to the specific 
antigen in question, then washed and treated with a radiolabeled conjugate, which detects the 
bound antibodies. After washing, the membrane is exposed to an X-ray film to produce an 
autoradiograph. The bands of antigen that have been bound to the antibodies are thereby made 
visible and can be quantified. The immunoblotting procedure for assessment of COX-1 and -2 
expressions has previously been described in detail (Ekerhovd et al, 2000). In our study a 
monoclonal antibody raised against purified ovine COX-1 (Cayman Chemical Company, Ann 
Arbor, MI, USA), diluted 1:1000, was used for measurements of COX-1 expression. For 
determination of COX-2, a monoclonal antibody raised against a synthetic peptide from the 
human COX-2 580–599 amino acids sequence (Cayman Chemical Company), diluted 1:1000, 
was used. As positive controls commercially available standards, human COX-1 
electrophoresis standard and human COX-2 electrophoresis standard (Cayman Chemical 
Company), were used. 
 
Immunohistochemistry  
Immunohistochemistry is used for localizing substances in tissue sections exploiting the 
principle of antibodies binding specifically to antigens. Visualizing an antibody-antigen 
complex can be accomplished in a number of ways. Most commonly, an antibody is 
conjugated to an enzyme, such as peroxidase, that catalyzes a color-producing reaction. 
Alternatively, the antibody can also be tagged to a fluorophore. The antibodies used for 
specific detection can be polyclonal or monoclonal. Monoclonal antibodies are generally 
considered to exhibit greater specificity as compared with polyclonal antibodies. However, 
the risk of using monoclonal antibodies is that the epitope can be damaged. Polyclonal 
antibodies are a heterogeneous mix of antibodies that recognize several epitopes. There are 
two strategies used for the immmunohistochemical detection of antigens in a tissue, the direct 
method (Figure 13) and the indirect method (Figure 14). 
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Figure 13. The direct method of immunohistochemical staining uses one labeled 
antibody, which binds directly to the antigen being stained for. 
The direct method is a one-step staining method. It involves a labeled antibody reacting 
directly with the antigen in tissue sections. This technique utilizes only one antibody and the 
procedure is therefore simple and rapid. However, in some cases it may lack sensitivity due to 
little signal amplification and it is less common than the indirect method. 
 
 
Figure 14. The indirect method of immunohistochemical staining uses one antibody 
against the antigen being probed for, and a second, labeled, antibody against the 
primary antigen-antibody complex. 
 
The indirect method involves an unlabeled primary antibody (first layer) which reacts with 
tissue antigen, and a labeled secondary antibody (second layer) which reacts with the primary 
antigen-antibody complex. This method is more sensitive due to signal amplification through 
several secondary antibody reactions with different antigenic sites on the primary antibody. 
The second layer antibody can be labeled with a fluorescent dye or an enzyme. It is possible 
to control the sensitivity of the test either by leaving out the primary antibody or by 
preabsorption. Preabsorption is a procedure which aims to eliminate cross-activity of the 
antibody. Antibodies that bind non-specifically to different proteins are eliminated and 
antibodies that react with the protein of interest will remain. 
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In this study the indirect method, peroxidase staining and monoclonal antibodies were used. 
Tissue specimens for immunohistochemistry were embedded in OCT (Sakura Finetek, 
Zoeterwoude, The Netherlands). Sections, 6 µm thick, were rinsed in phosphate-buffered 
saline (PBS), treated with 0.3% hydrogen peroxide in methanol for 30 min, and then exposed 
to normal horse serum (Vector Laboratories Inc., Burlingame, CA, USA) for 20 min at room 
temperature. They were then incubated with the primary monoclonal antibody against either 
COX-1 or COX-2 (Cayman Chemical Company) diluted 1:100 in 1% bovine serum 
albumin/PBS at 4ºC overnight. The sections were rinsed in 0.05% Triton-X (Sigma Chemical 
Company, St. Louis, MO, USA) in PBS and then incubated with biotinylated horse anti-
mouse immunoglobulin G (Vector Laboratories) as secondary antibody for 30 min followed 
by the addition of avidin–biotin peroxidase complex (Vector Laboratories) for 60 min. To 
visualize immunoreactivity the specimens were exposed to 0.05% 3´, 3´-diaminobenzidine-
tetrahydrochloride (Sigma Chemical Company) in PBS containing 0.03% hydrogen peroxide 
for 7 min. Two sections prepared from different levels of the cervical specimens were 
prepared from each of the women in the IMN and the placebo group, respectively. Negative 
controls were treated with PBS without any monoclonal antibody. Sections of epithelial 
ovarian carcinoma were used as positive controls.     
Statistical analysis  
Statistical analysis for immunoblotting was performed using the Mann–Whitney U-test. The 
results were expressed as median and range. A p <0.05 was considered to be statistically 
significant. For immunohistochemical analysis, the slides were examined by two independent 
observers using light microscopy. Localization of positive staining was carried out, but no 
attempt to quantify staining by objective methods was performed. 
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Paper IV – A double-blind randomized controlled clinical trial 
This investigation was conducted as a small pilot study where 24 patients were included. The 
primary outcome was the effect of the combination of oxytocin (the common agent used for 
treatment of retained placenta) and nitroglycerin on retained placenta. Secondary outcomes 
were maternal and fetal side effects and maternal hemodynamic effects. The trial was 
designed as a prospective, double blind, randomized controlled study. Inclusion criteria were 
uncomplicated singleton pregnancy with spontaneous vertex delivery of a healthy child. 
Exclusion criteria were gestation less than 37 weeks, postpartum hemorrhage requiring 
immediate intervention, uterine malformation, intolerance to nitroglycerin, maternal age less 
than 18 years, suspected placental accretism, and serious maternal disease, defined as daily 
use of medication.  
 
 
 
 
Figure 15. Schematic procedure of retained placenta from time of delivery of infant. 
 
During the recruitment period, all women who underwent vaginal delivery had standard active 
management of the third stage of labor according to written hospital protocols, including 
intravenous or intramuscular administration of 5 IU oxytocin (Syntocinon®, Novartis, Täby, 
Sweden) within minutes after delivery of the neonate. Maternal effort was encouraged to 
expel the placenta. If this was insufficient, controlled umbilical cord traction was used. This 
procedure involved applying steady, gentle traction to the cord with a Kelly clamp while 
30 min                                 Oxytocin 10 IU 
35 min                                Umbilical cord traction 
                                            (max for 5 min) 
40 min                                Randomization (placebo or nitroglycerin) 
 
50 min                               1mg nitroglycerin sublingually (n=12) or 
                                           Placebo tablets sublingually      (n=12) 
55 min                               Umbilical cord traction 
                                           (max for 5 min) 
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providing counter tracking against the uterine fundus. If the placenta still remained 
undelivered 30 min after delivery of the neonate an additional dose of 10 IU oxytocin was 
given intravenously to induce more efficient uterine contractions and thus promote placental 
separation. Five minutes later a new active attempt to deliver placenta was performed in a 
similar way. If placenta remained undelivered after 40 minutes the women were asked to be 
included in the study and randomization was carried out by means of numbered opaque, 
sealed envelopes prepared with random-number tables. This procedure was performed by a 
research nurse. Once the diagnosis of retained placenta had been made, intravenous infusion 
was initiated and all women were hemodynamically monitored. Figure 15 shows the whole 
procedure as a flow chart from delivery of the infant to placental separation. It is important to 
emphasize the interval of at least five minutes between medication and umbilical cord traction 
since the half-life of sublingual nitroglycerin is approximately three minutes. The sublingual 
administration was chosen instead of intravenous administration just to simplify the method. 
Neither the participating women nor the obstetrician on duty were aware of the agent 
administered. If placenta was not expelled within 60 minutes, manual removal of the placenta 
was performed at the operating theatre under regional or general anaesthesia. To reduce 
postoperative hemorrhage, 5 IU of oxytocin was routinely administered intravenously at the 
end of the operative manual removal. Maternal blood pressure and pulse rate were measured 
immediately prior to the sublingual administration of either nitroglycerin or placebo tablets. 
These measurements were repeated 15 min later for assessment of possible hemodynamic 
effects caused by the nitroglycerin tablets. Blood loss during the third stage of delivery was 
registered in each case. In addition, all the women completed a questionnaire about possible 
side effects of nitroglycerin. 
 
Statistical analysis 
A sample size of 24 women (12 in each group) was calculated to yield a power of 90% at the 
5% significance level when assuming a success rate of 80% in the treated group compared to 
a 20% success rate in the placebo group. Mean±SD and range were calculated for descriptive 
purposes. For statistical comparison the Student’s t-test was used for continuous variables and 
the Chi squared test was used for dichotomous variables. 
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RESULTS AND COMMENTS 
 
Paper I 
Results 
All 60 women included in the study underwent uncomplicated delivery by caesarean section. 
No serious maternal complications or signs of fetal distress resulting in specific medication or 
emergency caesarean section. All infants were healthy and had full Apgar scores (9-10) at 5 
minutes, normal pH-values in the umbilical artery and none needed specific neonatal 
surveillance. There were no complications associated with the measurement of cervical 
distensibility. Table 3 shows the results of primary outcome in the study.  
 
Results - efficacy
IMN (n=30)            Placebo (n=30)     p-value
________________________________________________________
Cervical length (mm)          
0 min 36.3±3.3                 35.1±2.7                ns
36 (30-42)              35 (30-41)            
210 min          36.1±3.1                 35.1±2.7                ns
36 (30-42)              35 (30-41)
Cervical 
distensibility (N)             2.7±1.2                   6.4±2.1               <0.0001             
(cumulative force to dilate              2.5 (1-5)                 6 (3-10)
cervix from 5 till 10 mm) 
________________________________________________________
Data are shown as mean±SD, median och range (min-max), ns=not significant
 
Table 3. Effect on cervical distensibility measured by a cervical tonometer following  
4 hours of intravaginal treatment with 40mg of IMN. N=Newton. 
 
There was a clear significant effect on cervical distensibility. The average distensibility 
measured in Newton in the treated group was approximately half of the distensibility in the 
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placebo group (p <0.0001). However, no change in cervical length could be measured by 
transvaginal ultrasonography approximately 210 minutes after administration of the NO 
donor. There were no significant differences in mean age, gestational age, pretreatment 
Bishop score, and treatment interval between the two groups. 
 
Secondary outcome measures were maternal and fetal side effects. 
  
Safety - mother
_________________________________________________________________________________
IMN (n=30)           Placebo (n=30)          p-value
_________________________________________________________________________________
Maternal systolic blood pressure (mmHg)                       
initially 112±6.9                110.7±7.5                   ns
110 (95-125)         110 (100-130)
at 180 min             105.5±5.5     116.0±6.5                   <0.001
105 (90-120)         115 (100-130)
Maternal diastolic blood pressure
initially 74.5±4.4                73.0±4.8                     ns
75 (70-80)             70 (65-80)
at 180 min              64.3±6.0               74.0±4.6                      <0.0001
65 (55-75)             75 (65-85)
Maternal pulse rate initially 73.2±8.3                71.7±7.4                     ns
72 (55-85)             72 (60-85)
at 180 min              84.0±8.4               76.5±8.3                      <0.01
85 (65-95)             75 (60-90)
Intraoperative blood loss                                   346.7±140.7          360.0±122.1              ns
300 (200-600)       400 (200-600)
_________________________________________________________________________________
Data are shown as mean±SD, median and range, ns=not significant
 
Table 4. Maternal hemodynamic effects following vaginal treatment with 40 mg of IMN. 
 
Isosorbide mononitrate is a known vasodilatator. Therefore, it is important to evaluate 
possible effects of the treatment on maternal blood pressure and pulse rate. In the IMN treated 
group there were significant effects in decrease of both systolic and diastolic blood pressure. 
The mean maternal pulse rate in the group 180 minutes after intravaginal administration was 
84.0 beats/min. In the placebo group, the mean maternal pulse rate at this time point was 76.5 
beats/min. Thus, a significant difference of 7.5 beats/min in mean maternal pulse rate was 
measured (p <0.01). However, as can be seen in Table 4, none of the women suffered from a 
clinically important decrease in blood pressure. Thus, no treatment for low blood pressure or 
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high pulse rate was needed. The lowest systolic blood pressure measured was 90 in the treated 
group and the lowest value in diastolic blood pressure was 55. No difference in total blood 
loss was registered between the groups and no woman needed blood transfusion. The mean 
blood loss in the treated group was 300 ml compared to 400 ml in the placebo group (ns). 
 
Maternal side effects
_______________________________________         
IMN            placebo      p-value
_______________________________________         
1.Headache 2.97±1.94 1.00±1.68     <0.001
3 (0-7)          1 (0-5)
2.Hot flushes        1.27±1.96    0.53±1.22    ns
0 (0-6)         0 (0-5)
3.Palpitation         1.83±1.93    0.63±1.33 <0.01
2 (0-6)         0 (0-4)
4.Dizziness           0.73±1.57    0.43±1.07    ns
0 (0-5) 0 (0-4)
5.Abdominal pain 0.47±1.28    0.53±1.41     ns
0 (0-5)          0 (0-5)
6.Pelvic pain 0.33±1.03    0.33±0.96    ns
0 (0-4)          0 (0-4)
7.Nausea         0.10±0.55    0.10±0.55         ns
0 (0-3)          0 (0-3)
__________________________________
Data are shown as mean±SD, median and range,
ns, not significant
0
5
10
15
20
25
1 2 3 4 5 6 7
IMN
Placebo
Number of patients (n=30 
in each group)
Headache (1), p <0.001,
Palpitation (3), p <0.02,
Other side effects, p-values, ns
Intensity according to VAS-scale
 
Table 5. Maternal side effects of IMN treatment. 
 
The most frequent symptomatic side effect in the IMN group was headache, experienced by 
24 of 30 women (Table 5). In the placebo group, 9 of 30 women reported headache 
immediately before the start of caesarean delivery (p <0.001). In addition, a significant 
increase (p <0.02) in frequency of palpitations was registered in women treated with IMN at 
this time point. There was no statistically significant difference in reported symptoms 
regarding hot flushes, dizziness, abdominal pain, pelvic pain, and nausea between the two 
groups. According to the results of the questionnaire, the side effects were not regarded as 
serious. None of the women required medical treatment due to the side effects. 
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Neither the umbilical artery resistance index (RI) nor the pulsatility index (PI) was influenced 
by IMN 180 minutes after intravaginal administration (Table 6). All CTGs intermittently 
performed during the preoperative observational period were normal and without any signs of 
fetal distress. Thus, fetal heart rate was within the normal range (110-150 beats/min) in all 
patients examined. No significant difference in fetal heart rate was registered between the 
IMN group and the placebo group 210 minutes after intravaginal administration. Umbilical 
arterial pH and Apgar score did not differ between the two groups. 
 
Safety - infant
_________________________________________________________________________________  
IMN (n=30)                placebo (n=30)              p-value
_________________________________________________________________________________
Pulsatility index                                               
initially                                           0.82±0.06                  0.81±0.07                       ns
0.82 (0.68-0.94)         0.80 (0.70-0.96)
at  180 min                                         0.79±0.06                  0.80±0.06                       ns
0.80 (0.66-0.92)         0.80 (0.66-0.92)
Resistance index
initially                                           0.58±0.05                   0.57±0.05                      ns
0.58 (0.48-0.67)          0.57 (0.48-0.66)
at 180 min                                          0.57±0.05                   0.57±0.06                      ns
0.56 (0.49-0.68)          0.56 (0.50-0.68)
pH in a.umbilicalis                                             7.34±0.03                   7.33±0.02                      ns
7.34 (7.28-7.38)         7.34 (7.29-7.38)
Fetal heart rate
initially                                           135.5±9.5                   135.0±10.4                    ns 
135 (115-150)            135 (115-150)
at 210 min                                          135.3±8.2                   135.8±7.6                       ns
135 (120-150)            135 (115-145)                   
Apgar score  at 5 min                                           9.8±0.4                       9.9±0.3                         ns
10 (9-10)                    10 (9-10)  
_________________________________________________________________________________             
Data are shown as mean±SD, median and range, ns=not significant
 
Table 6. Registered fetal parameters in the IMN group and the placebo group. 
 
Comments 
This study demonstrated that 40 mg of vaginally administered IMN increases cervical 
distensibility following 4 hours of treatment in pregnant women at term. Thus, one can 
conclude that the time interval of 4 hours and the dosage seems to be sufficient to promote 
cervical ripening. The result is in accordance with previous reports on the effect of 40 mg of 
IMN on human cervical distensibility in first trimester pregnancy (Thomson et al, 1997). In 
the current study, no change in cervical length was observed by transvaginal ultrasonography 
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210 minutes after intravaginal application of IMN. A cervical response characterized by an 
increased distensibility and no change in cervical length seems to be typical for NO donors. 
This effect may partly be due to the fact that NO does not induce uterine contractions. A 
similar effect on the cervix has previously been demonstrated after local treatment with the 
NO donor sodium nitroprusside in guinea pigs during advanced pregnancy (Chwalisz et al, 
1997).  
 
When introducing a medical agent for a new indication, as is the case for NO donors as 
cervical ripeners, it is important not only to evaluate the efficacy of the agent but also possible 
side effects. When using NO donors for cervical ripening at term one has to consider possible 
adverse effects on both the mother and fetus. Nitric oxide donors have previously been used 
in obstetrics for uterine relaxing purposes at caesarean section, at vaginal breech delivery or to 
relieve intrapartum fetal distress related to uterine hyperactivity (Wessen et al, 1995; Mercier 
et al, 1997). They have also been used for treatment of preterm cervical dilatation (Rowlands 
et al, 1996). A recent study has also shown that transdermal nitroglycerin may reduce 
neonatal morbidity and mortality as a result of decreased risk of birth before 28 weeks (Smith 
et al, 2007). Intravenous nitroglycerin is known as a rapid relaxant with effect already within 
60 seconds. The vasodilating effect of NO, causing a decrease in blood pressure, must always 
be considered. However, in previous reports no serious maternal or fetal complications have 
been reported (DeSimone, 1990; Dufour et al, 1997; Chedraui and Insuasti, 2003). Isosorbide 
mononitrate is known to be a slow-releasing NO donor. When administered into the vagina in 
the late third trimester peak serum levels of IMN were still not achieved at 6 hours (Bates et 
al, 2003). Of importance is also the fact that when administered vaginally serum levels of 
IMN are significantly lower than when administered orally or intravenously, probably due to 
first passage through cervix and uterus. With lower serum levels of IMN when vaginally 
administered the risk of maternal and fetal hemodynamic effects of IMN may decrease, but 
must still be taken into consideration. Prior to the present study, only one report on maternal 
and fetal hemodynamics had been published (Nicoll et al, 2001). The results of our study are 
consistant with this previous study.  
 
Neither the umbilical artery resistance index nor the pulsatility index was influenced by 40 
mg of IMN 180 minutes after intravaginal administration. All CTG registrations intermittently 
performed during the preoperative observational period were normal and without any signs of 
fetal distress, fetal heart rate being within the normal range (110-150 beats/min) in all patients 
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examined. Nicoll and co-workers observed a difference in fetal heart rate at 60 minutes (a 
slight increase in the IMN group), but only at this time point during registration. This 
observation could not be verified in our study. No significant difference in fetal heart rate was 
registered between the IMN group and the placebo group 210 minutes after intravaginal 
administration. Umbilical arterial pH and Apgar score did not differ between the two groups. 
 
The results of maternal hemodynamic and side effects reveal a significant decrease in 
maternal blood pressure and increase in pulse rate, but seem to be of no clinical importance. 
Headache and palpitations were common side effects, but only one woman described any of 
the symptoms as having an intensity of 7 on a visual analogue scale between 0 and 10. Thus, 
almost all reported symptoms were of moderate intensity. None of the participating women 
needed medical treatment of the symptoms. 
 
 In summary, the results from this study indicate that 40 mg of IMN administered vaginally 
within 4 hours has an effect on cervical ripening without causing uterine contractions within 
this period of time. The number of women in this study is too small to make any conclusive 
statements regarding the safety of vaginally administered IMN. Headache and palpitations, 
experienced by the majority of treated women, may not be considered as minor side effect. 
Likewise, the reduction of systolic and diastolic blood pressures might be regarded as an 
important adverse reaction. Nevertheless, the current study indicates that intravaginal 
treatment with IMN is well tolerated by the women as well as the newborn infants. In 
addition, no adverse effects as to the infant were registered by CTG, Doppler ultrasound, 
umbilical arterial pH, and Apgar scoring. Later studies on vaginally administered IMN for 
cervical ripening at term have confirmed that IMN treatment compared to placebo or PG does 
not increase the risk of fetal distress. The present study indicated that IMN can be used 
clinically for cervical ripening. 
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Paper II 
Results 
All 200 women included in the study fulfilled the inclusion criteria and completed the study. 
There were no significant differences between the two groups with respect to maternal age, 
parity, and gestational age. The main purpose of this investigation was to evaluate the number 
of postterm women who went into labor within 16-24 hours after application of 40 mg of 
IMN in an outpatient setting. The results revealed that 22 out of 100 treated women compared 
to 8 women in the placebo group went into labor (p =0.01) before the return appointment the 
following day (table 7). Two women who went into labor following treatment with IMN 
underwent emergency caesarean section due to fetal distress. The other women who went into 
labor within 24 h had vaginal deliveries, except for one woman in the placebo group who had 
a caesarean section due to failure of progress.  Mean time from vaginal administration of 
tablets to the first painful contractions was 14.0 h in the IMN group and 15.3 h in the placebo 
group, respectively (ns). 
Results                                         
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Table 7. Illustration of the results regarding labor, amniotomy, caesarean section, and 
blood loss. 
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The 95% confidence interval (CI) for the difference between the proportions of women who 
went into labor was 0.04-0.24. Regression analysis with spontaneous labor as dependent 
variable and case-control status, parity, baseline cervical length and baseline Bishop score as 
independent variables, showed that case-control status and baseline Bishop score remained 
significant (p=0.003 and p=0.001, respectively). The odds ratio for going into labor was 4.0 
(95% CI 1.6-9.8) for the treatment group compared to the placebo group, and 2.0 (95% CI 
1.3-2.9) for each unit increase in baseline Bishop score. 
 
Cervical ripening assessed as cervical length measured by transvaginal ultrasound and 
modified Bishop score was only possible to evaluate among women who did not go into 
labor. Therefore, the women are divided into 2 groups: women who went into labor and 
women who did not (Table 8).  
Clinical data - mother
Total number of women                 IMN (n=100)               Placebo (n=100)                     p-value
_________________________________________________________________________________
Women in labor n=22                                    n=8 0.01
Bishop score at baseline                2.5±1.0 (1-4)                       3.1±1.0 (1-4)                           ns
Cervical length at baseline (mm)   28.9±8.6 (15-51)                 28.2±8.4 (17-42)                     ns
Parity
nulliparous                                12         6                                 ns
multiparous                               10          2                                  ns
Treatment interval to contractions      14.0±5.0 (4-23)                   15.3±4.2 (10-22)                     ns
(hours)
Women not in labor n=78                                   n=92
Bishop score at baseline               1.8±1.2 (0-5)                       2.0±1.1 (0-5)                           ns
at return appointment        1.7±1.4 (0-5)                       1.3±1.5 (1-5)                           ns
Cervical length at baseline            31.2±9.4 (10-55)                 31.1±8.2 (9-47)                       ns
at return appointment       -6.0±8.8 (5-31)                    -5.2±10.2 (10-40)                    ns
Parity 
nulliparous                              60          68                                ns
multiparous                             18           24                                 ns
_______________________________________________________________________________
Data are shown as mean±SD and range (min-max),  ns= not significant
 
Table 8. Clinical data of women who went into labor compared to women who did not 
go into labor.  
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There was no statistical difference between the groups in cervical length or Bishop score 
among the women who did not go into labor. Sixty-four women initially treated with IMN 
and 74 women in the placebo group had a Bishop score < 6 (ns). These women were given 1 
mg of PGE2 vaginally for further cervical ripening. In fourteen women in the IMN group and 
in eighteen women in the placebo group Bishop score was ≥6 (ns) and amniotomy was carried 
out for induction of labor.                                          
 
Side effects and maternal satisfaction
______________________________________________________________________________ 
IMN                Placebo              p-value    
(n=94)             (n=98)
______________________________________________________________________________
Positive experience                                             42/88               31/94                0.01a)
Negative  experience                                            7/88                 12/94
Recommendation of same treatment                       81/91 (89%)     71/90 (79%)      nsb)
to other women
VAS-scales
Headache (after 6 hours)                                 88 (94%)         8 (8%)               <0.0001a)
3.9±2.2*          0.1±0.6* 
(0-9)               (0-4)
Nausea (6 hours)                                         19 (20%)          5 (5%)               0.001a)
0.5±1.2*          0.1±0.4*
(0-6)                (0-2)
Uterine contractions (after 6 hours)                   50 (53%)          48 (48%)          nsa)
1.2±1.5*          1.1±1.6*
(0-7)                (0-8)              
_______________________________________________________________________________
*mean±SD, range (min-max), a) Mann-Whitney U-test,  b) Fisher exact test,  ns= not significant
 
Table 9. Maternal side effects and satisfaction. 
 
The most common side effect in women treated with IMN was headache, experienced by 88 
women (88%) (Table 9). The intensity of headache was reported to be moderate in most cases 
with a median value of 4.0 (range 0-9) on the visual analogue scale. In the placebo group 
eight women (8%) reported headache of mild or moderate intensity. Nausea of mild intensity 
was reported by 19 women (19%) in the IMN group and by five women (5%) in the placebo 
group. All other reported side effects were infrequent. 
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Ninety-four women (94%) in the IMN group and 99 women (99%) in the placebo group 
returned the questionnaire regarding how they had experienced the outpatient procedure. The 
vast majority of women in both groups were either positive or very positive to the treatment. 
Eighty-nine of the women (94.7%) in the IMN group and 93 of the women (93.9%) in the 
placebo group reported that they would recommend the procedure.  
 
Neonatal outcome
_______________________________________________________________________________
IMN           Placebo                         p-value
(n=100)       (n=100)
_______________________________________________________________________________
Birth weight (g)                   3867±476*        3955±484*                nsa)
(2505-5590)      (2990-5865)
Apgar score (5 min)             9.5±1.1*            9.6±0.9*                    nsb)
(2-10)                (6-10)
pH i a.umb                           7.2±0.1*            7.2±0.1*                    nsa)
(6.84-7.43)        (6.97-7.37)
Apgar score <7  (5 min)       2                        1        nsc)
pH in a.umb <7.05  (n)         4                        8       nsc)
Admission to NICU (n)        13**                    9***       nsc)
______________________________________________________________________________
*mean±SD, range. a) independent samples t-test b )Mann-Whiney U-test
c) Fisher exact test, ns=not significant
**cause: infection(4), general seizures(2), heart disease(2), meconium aspiration(3), high bilirubin 
levels(1), hypoglycemia(1)
***cause:infection(4), heart disease(1), meconium aspiration(1), nutritional problems(2), 
hypoglycemia(1)
 
Table 10. Clinical data on neonatal outcome. 
 
In the IMN group two infants suffered from general seizures. These infants were both 
delivered instrumentally by vacuum extraction due to threatening asphyxia. Both had normal 
pH values in the umbilical artery, but according to the medical records both vacuum 
extractions were difficult to perform. Both infants had general seizures of short duration, but 
subsequent examination with EEG showed normal patterns. Both infants have later developed 
normally and have no medication at one year of age. pH in the umbilical artery was  <7.05 
among eight infants in the placebo group compared to four infants in the IMN group. A total 
of three infants had Apgar score <5 after 5 minutes, but all these infants had pH >7.05 in the 
umbilical artery. To conclude, neonatal outcome was similar in both groups (Table 10). 
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Comments 
Chanrachakul and co-workers were the first authors to suggest that NO donors administered 
vaginally at term could have an effect on both cervical ripening and labor induction. They 
studied the effect of both IMN and GTN (NO donors) in three different trials on cervical 
ripening and labor induction and reported onset of labor in 27-39% (Chanrachakul et al, 
2000a; 2000b; 2003). In one study 40 mg of IMN was repeated vaginally up to three times 
every sixth hour and no hyperstimulation of the uterus with secondary fetal distress was 
observed. Our study confirms that 40 mg of IMN seems to be efficacious for cervical ripening 
and labor induction at term. The results also indicate that outpatient IMN induced cervical 
ripening is likely to be a safe procedure, since neither fetal nor maternal side effects of clinical 
importance were registered.  
 
In our study the primary outcome (onset of labor) was not as promising as earlier studies, as 
only 22 % went into labor. Isosorbide mononitrate is a slow releasing agent especially when 
administered vaginally. Bates and co-workers studied serum levels of IMN after vaginal 
administration of 40 mg of IMN. They observed that peak levels were not reached before six 
hours. It is therefore plausible that the effect of the treatment lasted longer than 16-24 hours, 
which was the cut off time for evaluation in our study, and that more women would have gone 
into labor if the return appointment time had been postponed. It is also important to stress that 
the women were postterm. A previous study has shown that cervical expression of NO 
metabolites was seen among only 60% of women postterm compared to 87% among women 
at term pregnancy (Väisänen-Tommiska et al, 2004). Thus, it has been suggested that reduced 
cervical NO production may contribute to prolonged pregnancy. Vaginal administration of an 
NO donor, as performed in the present study, could result in sufficient cervical levels of NO 
to promote efficacious cervical ripening and induction of labor. It could also be that repeated 
administration of IMN, which was the case in one of the cited studies, is likely to be more 
efficacious. In one study commencement of uterine contractions was found to be associated 
with increased levels of cervical NO metabolites (Väisänen-Tommiska et al, 2003). It has also 
been demonstrated that IMN induces cervical production of COX-2, an enzyme that is 
involved in PG synthesis (Ekerhovd et al, 2002). Prostaglandins, stimulating both cervical 
ripening as well as uterine contractile activity, may mediate the NO associated effects on 
labor induction. 
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The study was designed as a prospective double-blind randomized study in an outpatient 
setting. The women were not observed during the time of treatment until onset of labor or 
time for return appointment. This procedure was considered to be safe for several reasons. All 
women were carefully informed to return to the labor ward if onset of painful contractions or 
unforseen side effects of the treatment were experienced. In a previous study, single as well as 
repeated treatment with 40 mg of IMN for 24 hours had shown no adverse effects on the 
fetus. Furthermore, only women with normal pregnancy, normal fetal heart pattern and 
normal amniotic fluid index were included. When analyzing the results concerning fetal side 
effects one can conclude that there was no difference in neonatal outcome between the 
groups. Relatively many infants in the present study needed NICU care (n=22). This could be 
due to the fact that postterm pregnancies are associated with a higher fetal morbidity than 
term pregnancies. Comparing the two groups, more infants in the treated group needed NICU 
care (13 versus 9). However, the difference was not statistically significant. On the other 
hand, more infants in the placebo group (8 versus 4) had an umbilical artery pH <7.05.  This 
study has not revealed differences in fetal outcome according to Apgar score, umbilical pH 
and need of NICU care. However, larger studies of similar design are necessary before final 
conclusions can be made.   
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Paper III 
Results 
Analyses were based on cervical biopsies obtained from 24 women. Twelve women had been 
treated with 40 mg of IMN for 4 hours, while the other 12 women had been given placebo 
tablets. Western blotting revealed significant increase in COX-2, but not COX-1, following 
vaginal administration of 40 mg IMN. In the IMN group the median for COX-2 was 16.8 
compared to 1.5 in the placebo group, but the medians for COX-1 were similar in both groups 
(Table 11).  
                              
Results – immunoblotting
Significant increase in COX-2 (p<0.001). IMN: median 16.8 (8.1-31.7), placebo: median 1.5 (0.4-5.8)
No difference in COX-1 (ns). IMN: median 5.2 (0.7-19.5), placebo: median 5.0 (3.3-5.6)                     
 
Table 11. Results on cervical expression of COX enzymes.  
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Table 12. Illustration of correlation between case and control for COX-1 and COX-2. 
Case=treated women, ctrl=control group. 
 
Table 12 describes the correlation between cases and controls for the two enzymes. It shows 
that the correlation is strong for COX-1, but not for COX-2.  
 
Positive immunostaining for both COX-1 and -2 was found in smooth muscle of the vessel 
wall, in bundles of stromal smooth muscle, and in glandular and squamous epithelium. In 
addition, immunopositive cells, probably representing inflammatory cells, were observed as 
isolated cells or as clusters of cells. No difference in the distribution of COX-1 positive cells 
or staining intensity of these cells was observed between the two groups. Although the 
number of immunopositive cells per visual area was too low to make any statistical 
calculation there was an overall impression by the two independent observers that the staining 
for COX-2, especially in the ‘‘inflammatory’’ stromal cells, was stronger in women treated 
with IMN as compared with women given placebo tablets. In sections where the squamous 
epithelium was included, staining intensity was found to be stronger for COX-1 than for 
COX-2 (Figure 16). 
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Figure 16. Immunohistochemical staining for COX-1 and -2 in cervical specimens 
obtained from women treated with IMN and women given placebo tablets. Scale bars = 
50 µm. (a) Placebo. Positive staining for COX-1 is seen in smooth muscle of blood vessels 
(arrowhead), stromal smooth muscle (open arrow), and in stromal interstitial cells 
(arrow). (b) IMN treatment. Cervical tissue where positive staining for COX-1 is seen in 
smooth muscle of blood vessels (arrowhead) and in clusters of interstitial cells in the 
perivascular space (arrow). (c) Placebo. Positive staining for COX-2 is seen in smooth 
muscle (arrowhead) and in an isolated stromal cell (arrow). (d) IMN treatment. Positive 
staining for COX-2 is seen in smooth muscle of blood vessels (open arrow), stromal 
smooth muscle (arrowhead) and in perivascular and stromal cells (arrow). (e) IMN 
treatment. Positive staining for COX-1 is seen in epithelial cells (arrow). (f) IMN 
treatment. Positive staining for COX-2 is seen in epithelial cells (arrow). 
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Comments 
Immunohistochemistry did not reveal any difference in cell types that turned out to be COX 
immunopositive between the two groups of women. Nevertheless, it was an overall 
impression that the staining for COX-2, especially in interstitial cells, was more intense in 
women treated with IMN as compared to women in the placebo group. The aim of 
immunohistochemistry was only to describe the distribution of COX enzymes within the 
tissue, not to quantitatively measure the expression of COX enzymes. The results are in 
agreement with a study performed by Stjernholm-Vladic and co-workers (2004), who 
described the distribution of COX enzymes within cervical tissue at term parturition. 
 
The results indicate that NO donors administered vaginally stimulate endogenous COX-2 
production in cervical tissue. However, there was no increase in expression of COX-1. COX-
2 is typically undetectable in most tissues under normal physiological conditions but can be 
expressed at high levels following stimulation. Cervical ripening has been described as an 
inflammatory action as a result of influx of macrophages and inflammatory mediators. 
Therefore, the increased expression of COX-2, which is involved in inflammatory processes, 
but not of COX-1 (the constitutive isoform), following stimulation by IMN appears logical. 
Besides, several studies have demonstrated that NO can induce the expression of COX-2, 
thereby increasing PG synthesis (Salvemini et al, 1993; 1994; 1999; Davidge et al, 1995; 
Maul et al, 2003).  However, a recent study has shown that there is an increase in both 
cervical COX-1 and COX-2 at parturition (Stjernholm-Vladic et al, 2004). The present study 
could not verify that the expression of COX-1 was increased following NO stimulation. It is 
possible, though, that COX-1 increases gradually over a longer period of time. In our study 
cervical biopsies were obtained already within 4 hours after administration of NO donor, 
which could explain why COX-1 was not increased. Alternatively, NO preferentially has a 
stimulatory effect on COX-2. When immunoblotting is carried out to assess COX expression 
it is important to bear in mind that the binding to COX-antibodies comprises both active and 
inactive enzymes. Consequently, the semiquantitative estimation of the enzymes does not 
directly relate to enzyme activity. This means that one can only presume that the increase in 
COX-2 expression was due to new enzyme synthesis. As COX- enzymes catalyze the PG 
synthesis, our results indicate that an interaction between NO and PG synthesis is present in 
the uterine cervix at term. Nitric oxide exerts its effects either via cGMP as a second 
messenger or via cGMP-independent pathways. In cervical tissue specimens obtained from 
 57   
women before surgical termination of pregnancy in the first trimester, levels of cGMP as well 
as COX-2 are increased following intravaginal administration of IMN (Ekerhovd et al, 2002). 
However, Salvemini and co-workers (1993) presented evidence that NO mediated stimulation 
on PGE2 synthesis is cGMP independent. The pathway leading to COX activation by NO is 
unknown, but it may involve an interaction at the iron-heme center of the enzyme. It is known 
that COX contains an iron-heme center at the active site (de Groot et al, 1975) and that NO 
interacts with iron-containing enzymes (Karthein et al, 1987; Moncada et al, 1991). There is 
increasing evidence that there is a link between COX and NOS pathways. In a recent study, it 
was reported that misoprostol, a PGE1 analogue, stimulates cervical NO release in pregnant 
women and that the sensitivity of NO synthesis to misoprostol was enhanced at term 
(Väisänen-Tommiska et al, 2005). On the other hand, it has also been shown that NO 
stimulates PGE2 release from cervical tissue explants and that cultured cervical tissue after in 
vivo treatment with IMN increases PGF2α release significantly (Denison et al, 1999; 
Ledingham et al, 1999a) Thus, a chain reaction where the initial NO stimulation caused by 
PG is followed by an endogenous release of PG triggered by NO has been suggested 
(Väisänen-Tommiska et al, 2005). The interaction between NO and PG synthesis indicates a 
possible joint action of the two substances which may be of importance for optimal cervical 
ripening at term. 
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Paper IV 
Results 
In all women treated with combined oxytocin – nitroglycerin all placentas detached and were 
delivered as compared with just one placenta in women treated with oxytocin only (Table 13).   
 
Results
Number of women with delivered placenta after treatment with 
nitroglycerin (n=12) or placebo (n=12), p<0.0001
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Table 13. All 12 women treated with nitroglycerin had successful delivery of placenta, 
compared to only one out of 12 women in the placebo group. 
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Hemodynamic results
________________________________________________________
Before NG (n=12)              15 min after NG                   p-value
________________________________________________________
Systolic BP                   119.2±7.3 (110,130)           112.9±7.8 (100,125)             0.003
Diastolic BP                  76.2±5.7 (70,85)                 71.2±4.3 (65,80)                   0.001
Pulse                            76.7±5.4 (70,86)                 78.7±4.2 (74,86)                   NS
Before placebo (n=12)      15 min after placebo 
_______________________________________________________________________
Systolic BP                   117.1±7.2 (105,130)            114.6±6.2 (105,120)            0.026
Diastolic BP                  72.9±7.5 (60,85)                  71.7±6.5 (60,80)                  NS
Pulse                            75.5±5.7 (66,86)                  71.5±3.7 (62,76)                  0.004 
_______________________________________________________________________
Before and 15 min after NG  Before and 15 min after placebo                   
Difference in syst BP   -6.2±5.7 (-15,5)                    -2.5±3.4 (-10,0)                     NS
Difference in diast BP  -5.0±3.7 (-10,0)                    -1.2±3.1 (-5,5)                       0.013
Difference in pulse        2.0±3.5 (-4,6)                      -4.0±3.8 (-10, 2)                    0.001
_______________________________________________________________________
Data are shown as mean±SD, range. NS=not significant. BP=blood pressure                  
 
Table 14. Effect of the treatment on blood pressure and pulse rate. NG=nitroglycerin. 
 
In women treated with nitroglycerin there were hemodynamic side effects, as a decrease in 
systolic and diastolic blood pressure as well as an increase in pulse rate were registered. A 
decrease in systolic blood pressure in the placebo group was also measured. The differences 
between the two groups in diastolic blood pressure and pulse rate were statistically 
significant. No woman needed treatment for NO induced hemodynamic effects or other side 
effects. The blood loss was significantly less in the treatment group (p <0.0001). Headache 
was experienced by four women in this group. Two of the women reported headache of 
moderate intensity, while the other two women reported headache of mild intensity.  
 
Comments 
The aim of this study was to rule out whether combined treatment with oxytocin and 
nitroglycerin is effective in women with retained placenta. To our knowledge, sublingual 
nitroglycerin has never been used in combination with oxytocin or as a single treatment of 
retained placenta. Previous reports on nitroglycerin administered intravenously have shown to 
be effective in the management of retained placenta and with no serious effects on maternal 
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hemodynamics. This study confirms previous results on hemodynamic measurements, but of 
importance is to note, that no woman needed medical treatment for decreased blood pressure. 
Until more knowledge has been achieved in this matter it is recommendable that a running 
intravenous infusion always is given, and that only hemodynamically stable women with no 
excessive bleeding can be subjects for this treatment. The maternal side effects with headache 
proved to be of minor importance, but additional studies are needed before further 
conclusions can be made. One explanation to the encouraging results may be that the 
treatment was a sequential combination of oxytocin and nitroglycerin, both known to have an 
effect on retained placenta per se. However, it is interesting that these two agents seem to be 
efficacious, although they have different effects on uterine contractility. Oxytocin is known to 
cause uterine contractions, whereas nitroglycerin has a relaxing effect on the uterine body. As 
previously discussed, oxytocin has been used for many years for management of the third 
stage of labor. However, there are no conclusive data supporting that oxytocin shortens the 
third stage of labor (Combs and Laros, 1991). On the other hand, it seems as the use of 
oxytocin in the third stage of labor results in less blood loss (Rogers et al, 1998). It is 
important to note that in the present study no differentiation was made to identify the causes 
of retainment of placenta. The placenta can either be detached but trapped because of cervical 
spasm, or it can be completely or partially attached to the decidual wall. Ultrasonographic 
examination was not performed to differentiate between these circumstances. However, based 
on the clinical examination the placenta was assumed to be attached to the decidual wall. 
 
When placenta is retained the most common method to separate it from the uterine wall is by 
inducing uterine contractions either manually or by medication. Dynamic ultrasonographic 
imaging has demonstrated that retro-placental myometrial contractions are necessary for 
placental separation and that lack of retro-placental contractions results in retained placenta 
(Herman et al, 1993). Placenta is usually thought of as a non-contractile or passive organ 
(Herman et al, 1993). However, Farley and co-workers demonstrated that human placental 
anchoring villi have contractile properties (Farley et al, 2004). This finding supports the 
hypothesis that placenta has the ability to regulate its own intravillous volume. Farley also 
reported that NO may be involved in the regulation of the contractile properties, as GTN and 
SNP (NO donors) in her study, induced dose dependent relaxation of the villi. Furthermore, 
the fetal membranes contain all three isoforms of the enzyme necessary to synthesize NO 
(Marinoni et al, 1997; Dennes et al, 1997). The inducible isoform, iNOS, is specifically 
expressed during labor, both at term and preterm (Marinoni et al, 2000). Moreover, the fetal 
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membranes release NO metabolites (Ticconi et al, 1996). They are probably a major source of 
the increased levels of NO metabolites found in amniotic fluid at labor (Marinoni et al, 2000). 
In addition, NO donors can strongly stimulate PGE2 release by fetal membranes (Marinoni et 
al, 2000). It is reasonable to presume that NO release from the fetal membranes also exerts a 
relaxing effect on placental villi and therefore may play a role in the detachment of placenta. 
It seems likely that NO induced relaxation of anchoring villi is a prerequisite for the 
retroplacentar myometrium to contract and the placenta to detach. Additionally, Ticconi and 
co-workers (2004) showed that oxytocin modulates NO generation by human fetal 
membranes at term, which could explain the promising results of combining oxytocin and 
nitroglycerin. Oxytocin stimulates the release of NO, and by adding both substances when 
retained placenta the effect of combined treatment is likely to be significantly improved by 
joint action. According to this hypothesis it could be NO that plays a more important role than 
oxytocin in the mechanism of placental detachment.  
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GENERAL DISCUSSION 
 
In this thesis some aspects on the role of NO in cervical ripening, labor induction and 
placental detachment have been evaluated. It seems obvious that NO has an important role in 
all these processes, but many of its mechanisms of action are still unknown. The present thesis 
comprises clinical and experimental trials where two different NO donors, IMN and 
nitroglycerin, have been applied for the purpose of cervical ripening, labor induction and 
management of retained placenta. Before a medical agent can be accepted for clinical use 
three important questions have to be answered: 1) efficacy, 2) safety and 3) side effects of the 
agent. In this thesis attempts have been made to examine NO donors in respect to these 
questions.  
 
1) Efficacy: The results indicated that NO promotes cervical ripening since vaginal treatment 
with IMN resulted in increased cervical distensibility. This effect could be mediated by a 
stimulation of PG synthesis since vaginal administration of IMN induced increased expression 
of COX-2. In accordance with a cervical ripening effect of IMN it was also observed that 
vaginal treatment with IMN initiates onset of labor in postterm pregnancies. Nitroglycerin in 
sequential combination with oxytocin was found to be extraordinarily effective in the 
management of retained placenta. It seems likely that nitroglycerin plays a key role in this 
context.  
 
2) Safety: Safety aspects are extremely important in obstetric managements, as the clinical 
handling concerns two individuals - the fetus and mother. In three of the studies the safety of 
NO regarding the mother has been examined, while in two studies fetal safety was evaluated. 
As NO donors are known to be vasodilatating agents, effects on maternal circulation must be 
considered. In the present thesis treatment with NO donors showed effects on maternal 
hemodynamics since both IMN and nitroglycerin caused a significant decrease in blood 
pressure as well as an increase in pulse rate. However, these side effects were in no case of 
clinical importance since none of the women needed treatment due to hemodynamic 
instability. On the other hand, in the placenta study intravenous infusion was routinely used 
for prophylactic reasons to compensate for hypotension and blood loss. Due to the small 
number of women it is too early to draw definite conclusions as to hemodynamic adverse 
effects. On the other hand, nitroglycerin did not cause more bleeding compared to placebo. 
On the contrary, blood loss was significantly lower in women treated with nitroglycerin 
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compared to women treated with placebo probably due to the efficacy of the treatment. The 
extra time interval otherwise needed for removal of placenta under anaesthesia could thereby 
be avoided. Taken together, so far no serious maternal or fetal side effects following treatment 
with NO donors have been registered. However, interpretations have to be made with caution. 
In the present thesis, various parameters regarding fetal safety were examined. Prior to labor, 
examinations on umbilical artery resistance and pulsatility index, CTG and fetal heart rate 
were registered. Following delivery, umbilical artery pH, Apgar score and need of NICU care 
were registered. Compared to the placebo group no difference was observed concerning fetal 
side effects.   
 
3). Side effects: It was obvious that NO donors commonly caused headache, nausea and 
palpitations. However, according to the VAS scales the side effects were of mild or moderate 
intensity. Nevertheless, the side effects are not negligible as nearly 90% of the women in the 
outpatient labor induction study reported headache. Therefore, it was unexpected that the 
majority of the women not only reported satisfaction with the treatment but also expressed 
that they could recommend the treatment to other women. It is probably wise not to draw too 
strong conclusions based on these reports since many of the women were tired of their 
postterm pregnancies and wished labor to be induced. Although side effects of NO donors 
were common, the overall impression remains that they seemed to be well tolerated. 
 
Finally, in this thesis two aspects of importance need to be emphasized: The possibility of 
outpatient treatment with an NO donor for cervical ripening and labor induction, and the 
management of retained placenta by using a sequential adminstration of oxytocin and 
sublingual nitroglycerin. The study indicates that IMN administered vaginally for cervical 
ripening and labor induction is effective, safe and well tolerated. Hospital costs are increasing 
and there is a demanding need to limit these costs. Treatment for cervical ripening and labor 
induction are normally managed in an inpatient setting as PGs, commonly used for this 
purpose, may be associated with uterine hyperstimulation. Consequently, fetal monitoring is 
mandatory. Since NO donors do not cause uterine hypertonus the possibility to induce 
cervical ripening and labor in an outpatient setting arises. Besides, the labor induction rate 
seems to be increasing in many countries. If future studies confirm that NO donors are safe 
and effective the outpatient procedure could prove to be an alternative strategy. Such an 
approach would reduce hospital costs substantially and could also possibly contribute to 
higher maternal satisfaction with the labor induction procedure. The second aspect to 
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emphasize is the possible effect of nitroglycerin on management of retained placenta. Future 
studies are needed to verify that the sequential combination of a uterotonic agent, oxytocin or 
PG, and a relaxing agent, e.g. nitroglycerin, is an efficient treatment regimen for detachment 
of retained placenta. Since both nitroglycerin and PG tablets are inexpensive and easily 
stored, the combined treatment may be worldwide applicable. Excessive blood loss due to 
retained placenta can be avoided and many lives, especially in developing countries, can 
thereby be saved.  
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Vaginal administration of the nitric oxide donor isosorbide
mononitrate for cervical ripening at term: A randomized
controlled study
Erling Ekerhovd, MD, PhD, Maria Bullarbo, MD, Bjo¨rn Andersch, MD, PhD, and
Anders Norstro¨m, MD, PhD
Go¨teborg, Sweden
OBJECTIVE: Our aim was to examine the effect of the nitric oxide donor isosorbide mononitrate on the uterine
cervix at term and to evaluate possible adverse effects of this treatment.
STUDY DESIGN: Term pregnant women were randomly selected to receive either 40 mg vaginally
administered isosorbide mononitrate or placebo 4 hours before elective cesarean section. Cervical status,
maternal blood pressure, maternal pulse rate, fetal heart rate, umbilical arterial Doppler indices, and various
side effects were examined.
RESULTS: Isosorbide mononitrate induced a signiﬁcant increase in cervical distensibility. It also caused
a signiﬁcant change in maternal blood pressure and maternal pulse rate. In addition, the frequency of maternal
headache and palpitations was signiﬁcantly higher in the isosorbide mononitrate group versus the placebo
group. However, the intensity of these symptoms was moderate.
CONCLUSION: Vaginal administration of 40 mg of isosorbide mononitrate induces cervical ripening at term.
Although the majority of women experienced side effects, no serious clinical maternal or fetal adverse effects,
resulting in speciﬁc medication or emergency cesarean section, were diagnosed. (Am J Obstet Gynecol
2003;189:1692-7.)
Key words: Cervical ripening, isosorbide mononitrate, nitric oxide, side effects, term pregnancy
Cervical ripening, clinically diagnosed by softening,
effacement, and dilatation of the uterine cervix, is
commonly stimulated pharmacologically by the use of
vaginally administered prostaglandins before induction
of labor. However, prostaglandins may cause adverse
maternal and fetal effects, mainly because of their
stimulatory action on uterine contractions. It has been
estimated that about 5% of women have uterine hyper-
tonus after administration of prostaglandins for the
induction of cervical ripening.1 Uterine hypertonus often
results in abdominal pain and anxiety, but it may also
cause circulatory complications that could be fatal to the
unborn child.
An ideal agent for cervical priming would induce
adequate cervical ripening without adverse maternal and
fetal effects. During the last few years it has become clear
that intravaginal administration of nitric oxide donors,
such as isosorbide mononitrate and glyceryl trinitrate,
induces cervical ripening in first trimester pregnant
women before surgical termination of pregnancy.2,3 In
addition, pretreatment with the nitric oxide donor
isosorbide mononitrate has proved to be associated
with fewer side effects than the prostaglandin analog
gemeprost.4 On the basis of these studies, it has been
suggested that nitric oxide donors may produce cervical
ripening for the induction of labor, without causing
serious adverse effects.5,6
Before studies can be performed to determine the
efficacy of nitric oxide donors for cervical ripening prior
to induction of labor, it is important to examine the
clinical effect of local treatment with nitric oxide donors
on the uterine cervix as well as to evaluate possible adverse
maternal and fetal effects of this medical treatment at
term. In the current study we examined the effects of
40 mg of isosorbide mononitrate, administered in-
travaginally, in term pregnant women before elective
cesarean section. The clinical effect of this treatment on
the uterine cervix was measured by the use of a cervical
tonometer. Maternal blood pressure, maternal pulse rate,
various subjective maternal side effects, as well as arterial
umbilical blood flow, fetal heart rate, and Apgar score
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were registered.Moreover, the intraoperative blood loss at
subsequent operation was measured.
Material and methods
This double-blind, randomized, controlled study was
carried out at Sahlgrenska University Hospital, Go¨teborg,
Sweden. Before the initiation of the study, approval was
granted by the human ethics committee of Go¨teborg
University.
A total number of 60 white Swedish women scheduled
for elective cesarean delivery caused by breech pre-
sentation or psychologic reasons were included in the
study (Table I). Inclusion criteria were nulliparity,
gestational age of at least 37 weeks, uncomplicated
singleton pregnancy, normal cardiotocography, normal
arterial umbilical Doppler indices, and immature cervical
status (Bishop score <6 and cervical length $30 mm,
measured by transvaginal ultrasonography). Exclusion
criteria included pregnancy-associated diseases, cardiore-
spiratory disease, history of headache, alcohol abuse,
cigarette smoking, intolerance to isosorbidemononitrate,
and serious systematic diseases, defined as daily use of
medication.
All women included in the study were 2 to 7 days before
planned cesarean delivery fully informed of the nature
and scope of the study, as well as the potential risks. At
admittance about 6 hours before cesarean section,
cardiotocography was performed to ensure that fetal
heart activity was normal. After cardiotocography, a clin-
ical examination of the uterine cervix was performed to
confirm a persistent immature cervical status. Assessment
of the cervix included consistency, length, dilatation,
position, and station of the fetal presenting part as first
described by Bishop and later modified by Calder et al.7
Cervical length was also measured by transvaginal
ultrasonography. In addition, the umbilical artery re-
sistance index and the pulsatility index were determined
and maternal pulse rate and blood pressure were
recorded digitally. If inclusion criteria were fulfilled,
a signed informed consent was obtained from each
participant before recruitment.
The women were randomized to either of two groups:
(1) 40 mg of isosorbide mononitrate (two 20-mg tablets)
(Ismo, Boehringer Mannheim, Mannheim, Germany) 4
hours before the cesarean section or (2) two placebo
tablets of similar design as the isosorbide mononitrate
tablets 4 hours before the cesarean section. Randomiza-
tion was performed by means of numbered, sealed
envelopes prepared with random-number tables. Both
the isosorbide mononitrate and the placebo tablets were
administered into the posterior vaginal fornix by a re-
search nurse. Neither the participating women nor the
research nurse were aware of the agent administered.
Maternal pulse rate, maternal blood pressure, umbilical
artery resistance index, and pulsatility index were
recorded at baseline and at 180 minutes. Fetal well-being
was evaluated intermittently by cardiotocographic regis-
tration, fetal heart rate being specifically recorded at
baseline and 210 minutes after intravaginal administra-
tion. For measurement of cervical length, transvaginal
ultrasonography of the uterine cervix was conducted at
baseline and at 210 minutes. Ultrasonography was
performed by one and the same investigator, who was
unaware of the type of intravaginal agent used. Before
being transported to the operating theater, the women
were asked to complete a symptom questionnaire. This
questionnaire concerned the following symptoms: head-
ache, hot flushes, palpitations, dizziness, abdominal pain,
Table I. Characteristics and clinical data of women participating in the study
Isosorbide mononitrate
(n = 30) Placebo (n = 30) P value
Age (y) 29.2 ± 5.1 28.7 ± 4.7 NS
29 (20-39) 30 (20-37)
Gestational age (wks) 38.0 ± 0.5 38.3 ± 0.4 NS
38 (37.0-38.6) 38.3 (37.5-38.9)
Pretreatment Bishop score 3.3 ± 1.1 3.4 ± 1.3 NS
3 (2-5) 3 (1-5)
Treatment period until
cervical dilation (min)
253 ± 11.6
255 (240-270)
254 ± 12.4
255 (240-270)
NS
Cervical length
At 0 min 36.3 ± 3.3 35.2 ± 3.6 NS
36 (30-42) 35 (30-41)
At 210 min 36.1 ± 3.1 35.1 ± 2.7 NS
36 (30-42) 35 (30-41)
Cumulative force to dilate the cervix
to 10 mm (N)
2.7 ± 1.2
2.5 (1-5)
6.4 ± 2.1
6 (3-10)
<.0001
Umbilical pH value (arterial) 7.34 ± 0.03 7.33 ± 0.02 NS
7.34 (7.28-7.38) 7.34 (7.29-7.38)
Intraoperative blood loss (mL) 346.7 ± 140.7 360.0 ± 122.1 NS
300 (200-600) 400 (200-600)
Data are shown as mean ± SD, median and range (minimum-maximum). NS, Not significant.
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pelvic pain, and nausea. If any of the mentioned
symptoms were present, the women were also asked to
describe the intensity of the symptoms based on a visual
analog scale. For statistical assessment of the intensity of
the reported symptoms, each scale was later graded from
0 (no symptom) to 10 (symptom of maximal intensity).
At the operating theater, spinal anesthesia was given
and the women were placed in the lithotomy position.
The peak force (in newtons) required to dilate the cervix
was measured with a cervical tonometer8 connected to
cervical dilators with diameter from 5 to 10 mm, as
previously described.2 Measurement of cervical distensi-
bility was conducted by one and the same investigator,
who was not informed about the intravaginal agent
administered. Cesarean section was then performed.
Oxytocin (Syntocinon, Novartis, Ta¨by, Sweden), 10 U
administered intravenously, was given routinely after
delivery of the placenta. Intraoperative blood loss was
assessed at the end of each operation. All newborn infants
were examined immediately after birth and monitored
closely during the early postnatal adaptation period.
Apgar score was documented 1, 5, and 10 minutes after
birth. At the end of the study, the treatment allocation for
each study number was revealed and the data were
analyzed.
Statistical analysis. A sample size of 60 women in two
groups, estimated by the Altman nomogram,9 was
calculated to yield 80% power at the 5% significance level
of detecting a standardized difference of 0.75 N in the
cumulative force required to dilate the cervix. Mean ±
SD, median, and range were calculated for descriptive
purposes. For comparison between groups, the Mann-
Whitney nonparametric U test was used for continuous
variables and the Fisher exact test for dichotomous
variables. All tests were two tailed and conducted at
a 5% significance level.
Results
No serious maternal complications or signs of fetal
distress resulting in specific medication or emergency
cesarean delivery were diagnosed during the study. All 60
women participating in the study had uncomplicated
planned cesarean delivery.
Isosorbide mononitrate had a clear effect on the
distensibility of the uterine cervix whenmeasured 4 hours
after initiation of treatment (Table 1). The force necessary
to dilate the cervix was significantly lower in this group
versus the placebo group (P < .0001). However, no
change in cervical length could be measured by tran-
svaginal ultrasonography approximately 210 minutes
after administration of the nitric oxide donor.
There were no significant differences in mean age,
gestational age, pretreatment Bishop score, and treat-
ment period between the two groups (Table I). Maternal
systolic blood pressure, maternal diastolic blood pressure,
and maternal pulse were similar in the two groups before
intravaginal administration of either isosorbide mono-
nitrate 40 mg or placebo tablets (Table II). After
a treatment period of 180 minutes, both the mean
maternal systolic (P < .001) and diastolic (P < .0001)
blood pressures in the isosorbidemononitrate groupwere
significantly lower than in the placebo group. The mean
maternal pulse rate in the isosorbide mononitrate group
180 minutes after intravaginal administration was 84.0
beats/min. In the placebo group, the mean maternal
pulse rate at this time point was 76.5 beats/min. Thus,
a significant difference of 7.5 beats/min in mean
maternal pulse rate was measured (P < .01).
The most frequent symptomatic side effect in the
isosorbide mononitrate group was headache, experi-
enced by 24 of the 30 women (Table III). In the placebo
group, 9 of the 30 women reported headache immediately
before the start of cesarean delivery (P < .001). In addi-
tion, a significant increase (P < .01) in the frequency of
palpitations was registered in women treated with
isosorbide mononitrate at this time point. There was no
statistically significant difference in reported symptoms
regarding hot flushes, dizziness, abdominal pain, pelvic
pain, and nausea between the two groups. Generally, the
experienced side effects were not regarded as serious by
the women themselves, according to the results of the
questionnaire. None of the women required any kind of
medical treatment because of the reported side effects.
Neither the umbilical artery resistance index nor the
pulsatility index were found to be influenced by 40 mg of
isosorbide mononitrate 180 minutes after intravaginal
administration (Table II). All cardiotocographies inter-
mittently performed during the preoperative observa-
tional period were normal and without any signs of fetal
distress, fetal heart rate being within the normal range
(110-150 beats/min) in all patients examined. No
significant difference in fetal heart rate was registered
between the isosorbide mononitrate group and the
placebo group 210 minutes after intravaginal administra-
tion (Table IV). Umbilical arterial pH andApgar score did
not differ between the two groups. None of the newborn
infants needed specific neonatal surveillance.
Uterine tonus, after delivery of the placenta and
routine intravenous injection of 10 U of oxytocin, was
found to be normal, except in four cases. Two of these
cases were in the isosorbide mononitrate group. In each
case, an additional dose of 10 U of oxytocin was injected,
resulting in adequate tonus of the uterine body. No
significant difference in intraoperative blood loss was
found between the isosorbidemononitrate group and the
placebo group.
Comment
The current study demonstrates that intravaginal
administration of 40 mg of isosorbide mononitrate for
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a period of 4 hours makes the uterine cervix more
distensible in termpregnant women. The study also shows
that maternal blood pressure and maternal pulse rate are
significantly changed 180 minutes after administration of
isosorbide mononitrate. However, none of these changes
resulted in specific medical treatment. Cardiotocography,
umbilical Doppler indices, as well as fetal heart rate, were
always normal during the observation period until elective
cesarean section was performed. Most important, neither
the term pregnant women nor the newborn infants
showed any signs of serious adverse effects caused by the
intravaginal treatment.
The finding that nitric oxide donors, such as
isosorbide mononitrate and glyceryl trinitrate, induce
Table II. Mean maternal blood pressure, heart rate, UA PI, and resistance index at 0 and 180 minutes
Isosorbide mononitrate (n = 30) Placebo (n = 30) P value
Maternal systolic blood pressure (mm Hg)
At 0 min 112.0 ± 6.9 110.7 ± 7.5 NS
110 (95-125) 110 (100-130)
At 180 min 105.5 ± 5.5 116.0 ± 6.5 <.001
105 (90-120) 115 (100-130)
Maternal diastolic blood pressure (mm Hg)
At 0 min 74.5 ± 4.4 73.0 ± 4.8 NS
75 (70-80) 70 (65-80)
At 180 min 64.3 ± 6.0 74.0 ± 4.6 <.0001
65 (55-75) 75 (65-85)
Maternal pulse rate (beats/min)
At 0 min 73.2 ± 8.3 71.7 ± 7.4 NS
72 (55-85) 72 (60-85)
At 180 min 84.0 ± 8.4 76.5 ± 8.3 <.01
85 (65-95) 75 (60-90)
Pulsatility index
At 0 min 0.82 ± 0.06 0.81 ± 0.07 NS
0.82 (0.68-0.94) 0.80 (0.70-0.96)
At 180 min 0.79 ± 0.06 0.80 ± 0.06 NS
0.80 (0.66-0.92) 0.80 (0.66-0.92)
Resistance index
At 0 min 0.58 ± 0.05 0.57 ± 0.05 NS
0.58 (0.48-0.67) 0.57 (0.48-0.66)
At 180 min 0.57 ± 0.05 0.57 ± 0.06
0.56 (0.49-0.68) 0.56 (0.50-0.68)
Data are shown as mean ± SD, median and range (minimum-maximum). NS, Not significant.
Table III. Number of patients with side effects in the period after administration of either isosorbide mononitrate
(40 mg) or placebo until cesarean section and the intensity of these registered side effects according to a visual
analog scale (0-10)
Side effects Intensity
Isosorbide mononitrate
(n = 30)
Placebo
(n = 30) P value
Isosorbide mononitrate
(n = 30)
Placebo
(n = 30) P value
Headache 24 9 <.001 2.97 ± 1.94 1.00 ± 1.68 <.001
3 (0-7) 1 (0-5)
Hot flushes 10 6 NS 1.27 ± 1.96 0.53 ± 1.22 NS
0 (0-6) 0 (0-5)
Palpitations 16 6 <.02 1.83 ± 1.93 0.63 ± 1.33 <.01
2 (0-6) 0 (0-4)
Dizziness 6 5 NS 0.73 ± 1.57 0.43 ± 1.07 NS
0 (0-5) 0 (0-4)
Abdominal pain 4 4 NS 0.47 ± 1.28 0.53 ± 1.41 NS
0 (0-5) 0 (0-5)
Pelvic pain 3 4 NS 0.33 ± 1.03 0.33 ± 0.96 NS
0 (0-4) 0 (0-4)
Nausea 1 1 NS 0.10 ± 0.55 0.10 ± 0.55 NS
0 (0-3) 0 (0-3)
Data are shown as mean ± SD, median and range (minimum-maximum). NS, Not significant.
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ripening of the uterine cervix has previously been dem-
onstrated in first-trimester pregnant women.2 Recently,
it was shown that intravaginal administration of either
40 mg of isosorbide mononitrate or 0.5 mg of glyceryl
trinitrate had ripening effects similar to that of 3 mg
of prostaglandin E2 on the induction of labor in
term pregnant women.10 In that study, little change in
cervical Bishop score was found after administration of
either of the two nitric oxide donors 4 hours after start
of treatment. In the current study, no change in
cervical length was observed by transvaginal ultrasonog-
raphy 210 minutes after intravaginal application of
isosorbide mononitrate. However, a significant increase
in cervical distensibility was measured by dilatation of
the cervical canal to a diameter of 10 mm by the use
dilators connected to a cervical tonometer. A cervical
response characterized by an increased distensibility
and no change in cervical length seems to be typical for
nitric oxide donors. This effect may partly be due to the
fact that nitric oxide does not induce uterine con-
tractions. A similar effect on the cervix has previously
been demonstrated after local treatment with the nitric
oxide donor sodium nitroprusside in guinea pigs
during advanced pregnancy.11
The competence of the cervix during pregnancy
appears to rely on an intact organization of the collagen
framework, which constitutes about 80% of the cervical
tissue.12 Degradation and disorganization of collagen
fibers at term seem to reduce cervical tensile strength and
may be a prerequisite for obvious clinical changes,
estimated by Bishop score, to occur. Among factors
regulating cervical ripening (ie, mechanical factors,
estrogens, cytokines, and other inflammatory agents),
prostaglandins are regarded to have a crucial role. Nitric
oxide appears to be involved in this process. We have
previously shown that vaginally applied isosorbide mono-
nitrate increases the expression of cyclo-oxygenase-2
in the cervix of first-trimester primigravid women.3
We therefore suggest that the increased distensibility
of the cervix, as observed in response to the nitric oxide
donor in this study, may be due to stimulation of local
prostaglandin synthesis. The short treatment period
(4 hours) and absence of uterine contractions may
explain the fact that no change in cervical length was
observed. Further, we have previously demonstrated in
vitro that nitric oxide relaxes cervical smooth muscle in
late pregnancy.6 Therefore, it cannot be excluded that the
observed increased cervical distensibility to some extent
also may be due to an effect on the smooth muscle
component.
Maternal and fetal hemodynamics after intravaginal
administration of isosorbide mononitrate in term preg-
nant women have recently been described in detail.13 In
a randomized controlled trial Nicoll et al recorded
maternal blood pressure, maternal pulse rate, and fetal
heart rate at baseline and then every 30 minutes until 360
minutes. In addition, umbilical artery resistance index
and pulsatility index were measured. They found that in
women who had been given isosorbide mononitrate
a significant decrease in both the maternal systolic and
diastolic blood pressures occurred during the study
period versus the control group. No changes in umbilical
artery Doppler indices were registered. The results of the
current study are in agreement with these previous
findings. Although significant changes in maternal
hemodynamics were recorded after administration of
isosorbide mononitrate, these effects did not prove to be
of clinical importance. As in the current study, none of the
participating women required treatment for hypotension
or tachycardia.
Themain symptoms after intravaginal administration of
isosorbidemononitrate reported in the current studywere
headache andpalpitations. It is well known that thesemost
common side effects are due to the vasodilatory action of
nitric oxide. In this study, a visual analog scale was used to
assess the frequency and intensity of side effects. Although
headache and palpitations were reported by the vast
majority of women in the isosorbide mononitrate group,
only one described any of the symptoms as having an
intensity of 7 on a visual analog scale between 0 and 10.
Table IV. Fetal heart rate at 0 and 210 minutes and Apgar score at 1, 5, and 10 minutes
Isosorbide mononitrate (n = 30) Placebo (n = 30) P value
Fetal heart rate
At 0 min 135.5 ± 9.5 135.0 ± 10.4 NS
135 (115-150) 135 (115-150)
At 210 min 135.3 ± 8.2 135.8 ± 7.6 NS
135 (120-150) 135 (115-145)
Apgar score
At 1 min 9.0 ± 0.6 9.1 ± 0.6 NS
9 (7-10) 9 (8-10)
At 5 min 9.8 ± 0.4 9.9 ± 0.3 NS
10 (9-10) 10 (9-10)
At 10 min 10.0 ± 0.0 10.0 ± 0.0 NS
10 (10-10) 10 (10-10)
Data are shown as mean ± SD, median and range (minimum-maximum). NS, Not significant.
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Thus, almost all the reported symptoms were of moderate
intensity. However, the fact that none of the participating
women had headache of high intensity or needed
medication, may be due to the relatively short treatment
period until cesarean delivery was performed. Because all
the participating women were informed about possible
adverse effects before giving their informed consent, the
relatively high number of women who had headache in
the placebo group may be due to the information given
before recruitment to the study.
Another aspect of intravaginal administration of
isosorbide mononitrate is the possible relaxing effect on
the uterine body. Several studies in vitro have shown that
nitric oxide has a relaxing effect of the myometrium.14-16
Glyceryl trinitrate has also been used as a tocolytic agent
for the treatment of preterm labor.17,18 A relaxing effect
on the uterine body after intravaginal treatment with
isosorbide mononitrate, causing uterine hypotonus and
thus increased blood loss, would preclude nitric oxide
donors for the induction of cervical ripening. As
demonstrated in the current study, intravaginal adminis-
tration of 40 mg of isosorbide mononitrate did not inhibit
uterine contraction after cesarean delivery as evaluated by
intraoperative and postoperative uterine tonus and blood
loss. None of the women had an intraoperative blood loss
of more than 600 mL and blood transfusions were never
necessary.
The number of women in this study is too small tomake
any conclusive statements regarding the safety of vaginally
administered isosorbide mononitrate. Headache and
palpitations, experienced by the majority of treated
women, may not be considered as a minor side effect.
Likewise, the reduction of systolic and diastolic blood
pressures might be regarded as an important adverse
reaction. Nevertheless, the current study points to the fact
that intravaginal isosorbide mononitrate treatment is well
tolerated by the women as well as the newborn infants.
We therefore conclude that isosorbide mononitrate
promotes cervical ripening at term by increasing the
distensibility of the tissue without causing serious clinical
maternal or fetal side effects. The use of nitric oxide
donors for the induction of cervical ripening at term may
thus prove to be a major therapeutic advance.
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OBSTETRICS
Outpatient vaginal administration of the nitric oxide donor
isosorbide mononitrate for cervical ripening and labor
induction postterm: a randomized controlled study
Maria Bullarbo, MD; Monica Eriksson Orrskog, MD; Björn Andersch, MD, PhD; Lena Granström, MD, PhD;
Anders Norström, MD, PhD; Erling Ekerhovd, MD, PhD
OBJECTIVE: Our aim was to examine the efficacy, safety, and accept-
ability of isosorbide mononitrate for cervical ripening and labor induc-
tion in women in an outpatient setting.
STUDY DESIGN: Two hundred pregnant women of at least 42 weeks’
gestation with an unripe cervix were randomly selected to receive vag-
inally either 40 mg isosorbide mononitrate or placebo tablets.
RESULTS: Twenty-two women treated with isosorbide mononitrate
went into labor within 24 hours compared to 8 women in the placebo
group (P  .05). In women who did not go into labor, cervical status
was similar in the 2 groups the next day. Headache was a common side
effect. No maternal or fetal side effects of clinical importance were
registered.
CONCLUSION: Outpatient cervical ripening and labor induction with
isosorbide mononitrate seems to be an effective, safe, and well toler-
ated procedure. The definitive clinical efficacy and safety needs to be
evaluated in larger series of patients.
Key words: cervical ripening, induction of labor, isosorbide
mononitrate, nitric oxide
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Postterm pregnancy, defined as apregnancy with a gestational length
of 294 days ormore, occurs in 5% to 10%
of all births.1 Postterm pregnancies are
associated with increased rates of multi-
ple maternal and fetal complications.2,3
Elective labor induction is therefore of-
ten carried out to reduce the risk of ad-
verse outcome, as an alternative to ex-
pectant management with serial fetal
monitoring and selective labor induc-
tion. The success of labor induction is
related to cervical ripening, and various
prostaglandin regimens are commonly
employed to ripen the cervix. However,
prostaglandin may cause adverse fetal
andmaternal effects, mainly due to their
stimulatory action on uterine contrac-
tions. It has been estimated that about
5% of women have uterine hypertonus
after administration of prostaglandin.4
For this reason, cervical ripening is car-
ried out on an inpatient basis so that the
fetus can bemonitored during the ripen-
ing process.
The ideal agent for cervical ripening
would induce adequate cervical ripening
without causing uterine contractions.
Since the lack of contractions obviates
the need for fetal monitoring, such an
agent could be given on an outpatient
basis. The advantages of outpatient cer-
vical ripening and labor induction in-
clude patient convenience, reduced
workload on labor and delivery units,
and reduced hospitalization costs.
Nitric oxide, a free radical gas with a
short half life, is thought to be a funda-
mental mediator of cervical ripening.5
Nitric oxide (NO) donors, such as
isosorbide mononitrate, nitroglycerin,
and sodium nitroprusside may prove to
be agents that can be administered in an
outpatient setting since they induce cer-
vical ripening without causing uterine
contractions or other adverse effects of
clinical importance during the ripening
process.6-11 In addition, several studies
have indicated that a substantial number
of women given isosorbide mononitrate
for cervical ripening at termgo into labor
within the next 24 hours.7,12 The present
studywas conducted in order to examine
the possible effect of isosorbidemononi-
trate on cervical ripening and initiation
of labor inwomen postterm and to study
the safety of this treatment in an outpa-
tient setting. Possible maternal and fetal
side effects as well as maternal satisfac-
tion with the outpatient induction pro-
cedure were also assessed.
MATERIALS AND METHODS
This double-blind, randomized, con-
trolled study was conducted at Sahlgren-
ska University Hospital, Gothenburg,
Sweden, andBoråsHospital, Borås, Swe-
den, between November 2002 and April
2005. Before initiation of the study, ap-
From the Department of Obstetrics and
Gynecology, Sahlgrenska University
Hospital, Gothenburg (Drs Bullarbo,
Andersch, Norström, and Ekerhovd), and
Department of Obstetrics and Gynecology,
Borås Hospital, Borås, Sweden (Drs Orrskog
and Granström).
Received Apr. 7, 2006; revised June 5, 2006;
accepted Aug. 15, 2006.
Reprint requests: Maria Bullarbo, MD,
Department of Obstetrics and Gynecology,
Sahlgrenska University Hospital, 41685
Gothenburg, Sweden;
maria.bullarbo@vgregion.se
0002-9378/$32.00
© 2007 Mosby, Inc. All rights reserved.
doi: 10.1016/j.ajog.2006.08.034
Research www.AJOG.org
50.e1 American Journal of Obstetrics & Gynecology JANUARY 2007
proval was granted by the human ethics
committee of Gothenburg University.
All women included were fully informed
of the nature and scope of the study, as
well as potential side effects. Written in-
formed consent was obtained from each
woman before recruitment.
Inclusion criteria were: (1) uncompli-
cated singleton pregnancy, (2) cephalic
presentation, (3) gestational age at least
42 weeks, (4) Bishop score 5, (5) nor-
mal amniotic fluid index measuring 5
cm, (6) reactive fetal heart pattern, and
(7) intact membranes. Gestational age
was assessed by a routine ultrasono-
graphic examination at 17-19 weeks of
pregnancy. Examination of the cervix in-
cluded an assessment of consistency,
length, dilatation, position, and station
of the fetal head as described by Bishop
and later modified by Calder and co-
workers.13 Measurement of the closed
cervical length was performed by trans-
vaginal ultrasonography.14 Exclusion
criteria included regular uterine contrac-
tions, cardiorespiratory disease, history
of headache, alcohol abuse, intolerance
to isosorbide mononitrate, and serious
disease, defined as daily use of medica-
tion.
A total number of 200 women fulfilled
the inclusion criteria and agreed to par-
ticipate in the study. The women were
randomized to either of 2 groups: (1) 40
mg of isosorbide mononitrate (2 20-mg
tablets) (Ismo, Roche, Basel, Switzer-
land) or (2) 2 placebo tablets of similar
design as isosorbide mononitrate. Ran-
domization was performed by means of
numbered, sealed envelopes prepared
with random-number tablets. Both the
isosorbide mononitrate and the placebo
tablets were inserted into the posterior
vaginal fornix by anobstetrician.Neither
the participating women nor the obste-
trician were aware of whether isosorbide
mononitrate or placebo tablets were ad-
ministered.
After administration of the tablets be-
fore returning home, each woman was
scheduled for an appointment the next
day. Thewomenwere also asked to com-
plete a symptom questionnaire regard-
ing possible maternal side effects during
the priming interval. This questionnaire
concerned the following symptoms:
headache, hot flushes, palpitations, diz-
ziness, nausea, and abdominal pain. For
assessment of the intensity of the symp-
toms a visual analogue scale graded from
0 (no symptom) to 10 (symptomofmax-
imal intensity) was used. If onset of labor
occurred before the next day, the women
were to contact the labor and delivery
unit according to routine praxis. If regu-
lar contractions had not been established
within the next day another cardiotocog-
raphy and assessment of the cervix were
performed. Induction of labor was then
carried out according to the local induc-
tion-of-labor protocol. Women with a
Bishop score  6 underwent am-
niotomy, while 1 mg of prostaglandin E2
(Minprostin, Pfizer, Täby, Sweden) was
administered vaginally for further cervi-
cal ripening if Bishop score was 6 or if
amniotomy was not feasible. The study
investigators were not involved with the
women’s inpatient cervical ripening or
intrapartum labor management.
Primary outcome measure was to
evaluate the efficacy of 40 mg of isosor-
bide mononitrate in promoting onset of
labor following cervical ripening for up
to 24 hours in an outpatient setting. Sec-
ondary outcome measures were assess-
ment of maternal side effects, mode of
delivery, blood loss, and neonatal out-
come in the 2 groups of women. Neona-
tal outcome was determined by Apgar
score, pH in the umbilical artery, and
need of neonatal intensive care. Finally,
when discharged from hospital each
woman was asked to return a question-
naire regarding her opinion about the
outpatient procedure and if she would
recommend it to other women.
STATISTICAL ANALYSIS
According to audits carried out in our
units approximately 7 out of 100 post-
term women would go into labor spon-
taneously within 24 hours. For eval-
uation of the efficacy of isosorbide
mononitrate for induction of labor a
power of 80%at the 5% significance level
was reached if 22 out of 100 women in
this group went into labor within 24
hours compared to 7 women in the pla-
cebo group. Thus, a total number of 200
women (100women in each group)were
included in the study. Fisher exact test
was used for assessment of the efficacy of
isosorbide mononitrate for induction of
labor. Changes in Bishop score and cer-
vical length were analyzed using 2 sam-
ple t test, while Mann-Whitney U-test
was used for assessment of maternal side
effects. All categorical outcomes in the 2
groups were compared using Fisher ex-
act test. Logistic regression was used to
assess the effect of isosorbide mononi-
trate, parity, baseline cervical length, and
baselineBishop score on spontaneous la-
bor outcome. All significance tests were
two-tailed. A P  .05 was considered to
be statistically significant.
RESULTS
There were no significant differences be-
tween the 2 groups of women with re-
spect to maternal age, parity, and gesta-
tional age (Table 1). All participating
women completed the study.
Twenty-two of the women (22%)
treated with isosorbide mononitrate and
8 of the women (8%) in the placebo
group went into labor before the return
appointment the following day (P .05;
Table 2). Mean time from vaginal ad-
ministration of tablets to the first painful
contractions was 14.0 hours in the
isosorbide mononitrate group and 15.3
hours in the placebo group, respectively.
The 95% confidence interval (CI) for the
difference between the proportions of
women who went into labor was 0.04-
0.24. Regression analysis with spontane-
ous labor as dependent variable and
case-control status, parity, baseline cer-
vical length, and baseline Bishop score as
independent variables, showed that case-
control status and baseline Bishop score
remained significant (P .003 and P
.001, respectively). The odds ratio for go-
ing into labor was 4.0 (95% CI 1.6-9.8)
for the treatment group compared to the
placebo group, and 2.0 (95% CI 1.3-2.9)
for each unit increase in baseline Bishop
score.
Two women who went into labor fol-
lowing treatment with isosorbidemono-
nitrate underwent emergency cesarean
section due to fetal distress. The other
women who went into labor within 24
hours had uncomplicated vaginal deliv-
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eries, except for 1 woman in the placebo
group who had a cesarean due to failure
of progress.
In women who did not go into labor,
Bishop score as well as cervical length
were found to be similar in the 2 groups
at the return appointment (Table 2). Six-
ty-four women initially treated with
isosorbide mononitrate and 74 women
in the placebo group had a Bishop score
 6. These women were given 1 mg of
prostaglandin E2 vaginally for further
cervical ripening. In 14 women in the
isosorbide mononitrate group and in 18
women in the placebo group Bishop
score was  6 and amniotomy was car-
ried out for induction of labor.
Neonatal outcome was similar in the 2
groups (Table 3).
The most common side effect in
women treated with isosorbide mononi-
trate was headache, experienced by 88
women (88%). The intensity of head-
ache was reported to be moderate in
most caseswith amedianof 4 (range 0-9)
on the visual analogue scale. In the pla-
cebo group 8 women (8%) reported
headache of mild or moderate intensity.
Nausea ofmild intensity was reported by
19 women (19%) in the isosorbide
mononitrate group and by 5 women
(5%) in the placebo group. All other re-
ported side effects were infrequent.
Ninety-four women (94%) in the
isosorbide mononitrate group and 99
women (99%) in the placebo group re-
turned the questionnaire regarding how
they had experienced the outpatient pro-
cedure. The vast majority of women in
TABLE 1
Basic data of women participating in the study
Isosorbide mononitrate (n  100) Placebo (n  100) P value
Age (y) 31.2 4.4 (21-41) 30.6 5.3 (19-43) NS
................................................................................................................................................................................................................................................................................................................................................................................
Parity (n)
................................................................................................................................................................................................................................................................................................................................................................................
Nulliparous 72 74 NS
................................................................................................................................................................................................................................................................................................................................................................................
Multiparous 28 26
................................................................................................................................................................................................................................................................................................................................................................................
Gestational age (wk) 42.2 0.3 (42.0-43.0) 42.1 0.2 (42.0-43.0) NS
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
Data are shown as mean  SD and range (minimum-maximum). NS, not significant.
TABLE 2
Clinical data of women who went into labor and women who did not go into labor
Total number of women Isosorbide mononitrate (n  100) Placebo (n  100) P value
Women who went into labor (n  22) (n  8) .01
................................................................................................................................................................................................................................................................................................................................................................................
Baseline Bishop score 2.5 1.0 (1-4) 3.1 1.0 (1-4) NS
................................................................................................................................................................................................................................................................................................................................................................................
Baseline cervical length (mm) 28.9 8.6 (15-51) 28.2 8.4 (17-42) NS
................................................................................................................................................................................................................................................................................................................................................................................
Parity
................................................................................................................................................................................................................................................................................................................................................................................
Nulliparous 12 6 NS
................................................................................................................................................................................................................................................................................................................................................................................
Multiparous 10 2
................................................................................................................................................................................................................................................................................................................................................................................
Interval between administration
of agent and first painful
contraction (h)
14.0 5.0 (4-23) 15.3 4.2 (10-22) NS
................................................................................................................................................................................................................................................................................................................................................................................
Women who did not go into
labor
(n  78) (n  92)
................................................................................................................................................................................................................................................................................................................................................................................
Bishop score
................................................................................................................................................................................................................................................................................................................................................................................
Baseline 1.8 1.2 (0-5) 2.0 1.1 (0-5) NS
................................................................................................................................................................................................................................................................................................................................................................................
Change at return appointment 1.7 1.4 (0-5) 1.3 1.5 (1-5) NS
................................................................................................................................................................................................................................................................................................................................................................................
Cervical length (mm)
................................................................................................................................................................................................................................................................................................................................................................................
Baseline 31.2 9.4 (10-55) 31.1 8.2 (9-47) NS
................................................................................................................................................................................................................................................................................................................................................................................
Change at return appointment 6.0  8.8 (5-31) 5.2  10.2 (10-40) NS
................................................................................................................................................................................................................................................................................................................................................................................
Parity
................................................................................................................................................................................................................................................................................................................................................................................
Nulliparous 60 68 NS
................................................................................................................................................................................................................................................................................................................................................................................
Multiparous 18 24
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
Data are shown as mean  SD and range (minimum-maximum). NS, not significant.
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both groups were either positive or very
positive to the treatment. Eighty-nine of
the women (94.7%) in the isosorbide
mononitrate group and 93 of the women
(93.9%) in the placebo group reported
that they would recommend the proce-
dure.
COMMENT
This study shows that 40 mg of isosor-
bidemononitrate seems to have an effect
on cervical ripening and induction of la-
bor postterm. The results also indicate
that outpatient isosorbide mononitrate
induced cervical ripening is likely to be a
safe procedure, since neither fetal nor
maternal side effects of clinical impor-
tance were registered.
Significantly more women treated
with isosorbide mononitrate went into
labor within 24 hours compared to
women in the placebo group. The result
is in line with previous reports where
27% to 39% of term pregnant women
went into active labor or had a favorable
Bishop score following cervical ripening
with either isosorbide mononitrate or
nitroglycerin for 24 hours.7,12,15 Thus, a
linkage between the degree of cervical
ripening or cervical level of nitric oxide
and time point for onset of contractions
may exist. In fact, in 1 study commence-
ment of uterine contractions was found
to be associated with increased levels of
cervical nitric oxide metabolites.16 It has
also been demonstrated that isosorbide
mononitrate induces cervical produc-
tion of cyclo-oxygenase 2, an enzyme
that is involved in prostaglandin synthe-
sis.17 Prostaglandins are known to have a
stimulating effect on uterine contrac-
tions. In addition, vaginally adminis-
tered isosorbide mononitrate increases
cervical tissue levels of cyclic guanosine
monophosphate (cGMP). This second
messenger of nitric oxide is thought to
promote relaxation of cervical smooth
muscle, a pathway which may be in-
volved in cervical ripening.18,19
Fortymilligrams of vaginally adminis-
tered isosorbide mononitrate have pre-
viously been demonstrated to stimulate
cervical ripening after a treatment inter-
val of 3-4 hours and to induce rearrange-
ment of the cervical ultrastructure in the
first trimester similar to the changes seen
during spontaneous cervical ripening at
term.10,17,20 In the present study, al-
though women treated with isosorbide
mononitrate had a higher mean Bishop
score than women given placebo tablets
at the appointment the next day, the dif-
ference in Bishop score was not signifi-
cant. However, only women who had
not gone into labor within 24 hours
could be examined. Thus, 22 of the 100
women (22%) treated with isosorbide
mononitrate could not be assessed. Since
almost all women who went into labor
had uncomplicated vaginal deliveries, it
is reasonable to conclude that cervical
ripening in these women was adequate.
In previous reports, a gradual increase in
Bishop score has been described follow-
ing vaginal administration of isosorbide
mononitrate at term when examined at
intervals of 3 hours until amniotomy or
onset of labor.7,12
Previously it has been demonstrated
that cervical nitric oxide production is
very low inwomenpostterm.Thus, it has
been suggested that reduced cervical ni-
tric oxide release may contribute to pro-
longed pregnancy.21 Vaginal adminis-
tration of a nitric oxide donor as
performed in the present study, could
therefore result in sufficient cervical lev-
els of nitric oxide to promote efficacious
cervical ripening and induction of labor.
In the present study, the effect of
isosorbide mononitrate was assessed
during a treatment interval of only 24
hours. Women who went into active la-
bor did not experience painful or regular
contractions before 14-23 hours after
administration of isosorbide mononi-
trate. A further increase in the effect of
isosorbide mononitrate would most
likely have occurred if vaginal adminis-
tration of the nitric oxide donor had
been repeated. A strategy with repeated
administration of the agent is normally
carried out when prostaglandin is em-
ployed for cervical ripening and labor in-
duction. Isosorbide mononitrate is
TABLE 3
Data on delivery and neonatal outcome
Isosorbide mononitrate (n  100) Placebo (n  100) P value
Mode of delivery
................................................................................................................................................................................................................................................................................................................................................................................
Vaginal delivery 86 83 NS
................................................................................................................................................................................................................................................................................................................................................................................
Cesarean section 14 17 NS
................................................................................................................................................................................................................................................................................................................................................................................
Blood loss (mL) 635 616 (150-3700) 566 449 (100-3500) NS
................................................................................................................................................................................................................................................................................................................................................................................
Blood loss 1000 mL (n) 14 12 NS
................................................................................................................................................................................................................................................................................................................................................................................
Birthweight (g) 3867 476 (2505-5590) 3955 484 (2990-5865) NS
................................................................................................................................................................................................................................................................................................................................................................................
Apgar score  7 at 5 minutes (n) 2 1 NS
................................................................................................................................................................................................................................................................................................................................................................................
Apgar score at 5 minutes 9.5 1.1 (2-10) 9.6 0.9 (6-10) NS
................................................................................................................................................................................................................................................................................................................................................................................
Umbilical artery pH 7.05 4 8 NS
................................................................................................................................................................................................................................................................................................................................................................................
Admission to NICU 13* 9† NS
................................................................................................................................................................................................................................................................................................................................................................................
................................................................................................................................................................................................................................................................................................................................................................................
Data are shown as mean  SD and range. NS, not significant; NICU, neonatal intensive care unit.
* Cause: infection (4), general seizures (2), heart disease (2), meconium aspiration (3), high bilirubin levels (1), hypoglycaemia (1).
† Cause: infection (4), heart disease (1), meconium aspiration (1), nutritional problems (2), hypoglycemia (1).
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known to be a slow-releasing nitric oxide
donor. When administered into the va-
gina in the late third trimester, peak se-
rum levels of isosorbide mononitrate
were still not achieved at 6 hours.22
Therefore, a treatment interval before
another dose of isosorbide mononitrate
is administered should clearly be more
than 6 hours.
The investigation confirms previous
reports that vaginally administered
isosorbide mononitrate does not induce
uterine hyperstimulation. No signs of
abnormal fetal heart rate until the active
phase of labor were registered. This find-
ing is in agreement with a recent report,
where no abnormal fetal heart tracings
were identified after isosorbide mononi-
trate therapy in 199 women at term in an
inpatient setting.11 Thus, the risk of fetal
compromise during the ripening process
seems to beminimal. In addition, no dif-
ference in mode of delivery, blood loss,
umbilical pH, Apgar score, or need for
neonatal intensive care was found be-
tween women treated with isosorbide
mononitrate and women who were
given placebo tablets.
Maternal preference for outpatient
cervical ripening and labor induction in
uncomplicated pregnancies, thereby po-
tentially improving patient convenience
and reducing hospital costs, has previ-
ously been described.23 The question-
naire clearly demonstrated thatmaternal
side effects caused by isosorbide mono-
nitrate were acceptable, although head-
ache of mild to moderate degree was
common. Maternal satisfaction and ac-
ceptability were found to be high, and
the vastmajority ofwomen reported that
they would recommend the outpatient
procedure to other women.
However, although this was a double-
blind randomized study, the high fre-
quency of headache in women treated
with isosorbide mononitrate may have
influenced their comments. Since the
women were informed about possible
side effects of the nitric oxide donor be-
fore being included in the study theymay
have guessed whether they had received
isosorbide mononitrate or placebo tab-
lets. This may have prompted them to
report higher satisfaction rates with the
novel regimen.
Taken together, this study indicates
that vaginally administered isosorbide
mononitrate for cervical ripening and
induction of labor seems to be safe, effec-
tive, and well tolerated. Further studies
are necessary to identify the ideal formu-
lation, dose, and frequency of adminis-
tration of nitric oxide donors, as well as
to confirm the safety of the procedure
when repeatedly administered. f
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Isosorbide mononitrate induces increased cervical expression of
cyclooxygenase-2, but not of cyclooxygenase-1, at term
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Abstract
Objective: Prostaglandin and nitric oxide (NO) are both known to be involved in cervical ripening at term. The aim of the study was to
investigate if NO has an effect on cervical expression of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), the two main
isoenzymes involved in prostaglandin synthesis, and to localize these enzymes within the cervix.
Study design: Women with an unripe cervix scheduled for elective caesarean section at term were randomly selected to receive vaginally
either the NO donor isosorbide mononitrate (IMN) or placebo 4 h before surgery. At the operating theatre, cervical tissue specimens were
obtained for immunoblotting and immunohistochemistry.
Results: Increased expression of COX-2 was found in specimens exposed to IMN compared to specimens obtained from women in the
placebo group. There was no difference in the expression of COX-1. Immunohistochemistry revealed similar localization of the two enzymes
in treated and untreated women.
Conclusions: Vaginal administration of IMN induces increased cervical expression of COX-2, but not of COX-1. This pathway may be of
importance in the process of cervical ripening at term.
# 2006 Elsevier Ireland Ltd. All rights reserved.
Keywords: Cervical ripening; Cyclooxygenase; Nitric oxide; Prostaglandin
1. Introduction
The biochemical events during cervical ripening resem-
ble an inflammatory reaction, involving influx of leukocytes,
an increase in extracellular water content, and rearrange-
ment of collagen fibres [1–3]. Prostaglandins have been
considered to be central mediators of cervical ripening [4].
Prostaglandin (PG) synthesis is catalysed by cyclooxygen-
ase (COX). The two main isoenzymes of cyclooxygenase,
COX-1 and -2, are differently regulated. COX-1 is
constitutively expressed in numerous tissue types and its
expression is, in general, not regulated. In contrast, COX-2 is
typically undetectable in most tissues under normal
physiological condition but can be expressed at high levels
following stimulation.
An endogenous nitric oxide (NO) system is present in the
human uterine cervix [5,6]. In addition, increased expression
of NO synthases, enzymes that catalyse NO production, has
been found in cervical biopsies at term [5,7,8]. Nitric oxide
donors, such as isosorbide mononitrate (IMN) and
nitroglycerin, have been documented to induce cervical
ripening in pregnant women [9,10]. Nitric oxide has a
multifunctional role in inflammation and various proin-
flammatory effects of NO have been described, including an
increase in vascular permeability, cytotoxity and tissue
damage, changes in glycosaminoglycan synthesis and
apoptosis. Apoptosis is known to play an important role
in cervical ripening [11]. Thus, several lines of evidence
indicate that NO is a mediator of cervical ripening.
Furthermore, an interaction between NO and PG synthesis
has been suggested to be present in the cervix at term [12].
Such a linkage between two proinflammatory substances
could be of importance in promoting cervical ripening.
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The aim of the present study was to investigate if NO has an
effect on cervical expression of COX-1 and -2 at term and to
localize the two enzymes within the cervix.
2. Materials and methods
2.1. Patients and tissue sampling
The study was approved by the ethics committee of
Gothenburg University. Twenty-four healthy women,
scheduled for elective caesarean section were, after
informed consent, included in the study. Inclusion criteria
were gestational length > 37 weeks, no former vaginal
delivery, uncomplicated singleton pregnancy and unripe
cervical status (Bishop score < 6). All women included
were 1–4 days before caesarean section informed of the
nature and scope of the study, as well as the potential side
effects of IMN. Cervical status was assessed in the morning
the day of caesarean section. If inclusion criteria were met,
the women were randomised to either of two groups: (1)
40 mg IMN (two 20-mg tablets) (ISMO1, Boehringer
Mannheim, Mannheim, Germany) 4 h before the caesarean
section or (2) two placebo tablets of similar design as IMN
4 h before caesarean section. Randomisation was per-
formed by means of numbered, sealed envelopes prepared
with random-number tablets. Twelve women were allocated
to each group. The tablets were administered into the
posterior vaginal fornix by an obstetrician. Neither the
participating women nor the doctor were aware of the agent
administered. At the operating theatre, spinal anaesthesia
was given and the women were placed in the lithotomy
position. Cervical tissue specimens were obtained trans-
vaginally from the anterior lip of the cervix by use of a
14 gauge Tru-Cut1 biopsy needle (Allegiance Healthcare
Corporation, McGore Park, IL, USA). Three cylindrical
biopsies of approximately 1.5  15 mm size (wet weight
25–40 mg) were obtained from each woman. The tissue
specimens were immediately transferred to liquid nitrogen
and frozen at 70 8C until analysis. Caesarean section was
then performed.
2.2. Immunoblotting
The immunoblotting procedure for assessment of COX-1
and -2 expression has previously been described in detail [6].
Briefly, a monoclonal antibody raised against purified ovine
COX-1 (Cayman Chemical Company, Ann Arbor, MI,
USA), diluted 1:1000, was used for measurements of COX-1
expression. For determination of COX-2 expression, a
monoclonal antibody raised against a synthetic peptide from
the human COX-2 580–599 amino acids sequence (Cayman
Chemical Company), diluted 1:1000, was used. As positive
controls commercially available standards, human COX-1
electrophoresis standard and human COX-2 electrophoresis
standard (Cayman Chemical Company) were used.
2.3. Immunohistochemistry
Tissue specimens for immunohistochemistry were
embedded in OCT (Sakura Finetek, Zoeterwoude, The
Netherlands). Sections, 6 mm thick, were rinsed in
phosphate-buffered saline (PBS), treated with 0.3% hydro-
gen peroxide in methanol for 30 min, and then exposed to
normal horse serum (Vector Laboratories Inc., Burlingame,
CA, USA) for 20 min at room temperature. They were then
incubated with the primary monoclonal antibody against
either COX-1 or COX-2 (Cayman Chemical Company)
diluted 1:100 in 1% bovine serum albumin/PBS at 4 8C
overnight. The sections were rinsed in 0.05% Triton-X
(Sigma Chemical Company, St. Louis, MO, USA) in PBS
and then incubated with biotinylated horse anti-mouse
immunoglobulin G (Vector Laboratories) as secondary
antibody for 30 min followed by the addition of avidin–
biotin peroxidase complex (Vector Laboratories) for 60 min.
To visualize immunoreactivity the specimens were exposed
to 0.05% 30,30-diaminobenzidine-tetrahydrochloride (Sigma
Chemical Company) in PBS containing 0.03% hydrogen
peroxide for 7 min. Two sections were prepared from each
of the women in the IMN and the placebo group,
respectively. Negative controls were treated with PBS
without any monoclonal antibody. Sections of epithelial
ovarian carcinoma were used as positive controls [13].
2.4. Data analysis
Statistical analysis for immunoblotting was performed
using the Mann–Whitney U-test. The results were expressed
as median and range. P < 0.05 was considered to be
statistically significant.
For immunohistochemical analysis, the slides were
examined by two independent observers using light
microscopy. Localization of positive staining was carried
out, but no attempt to quantify staining by objective methods
was performed.
3. Results
In all women included in the study the treatment interval
following administration of either IMN or placebo tablets
until caesarean section was uneventful. No side effects caused
by the NO donor or the placebo tablets were registered.
No statistical difference in the expression of COX-1 was
found in women treated with IMN (median 5.2; range 0.7–
19.5) compared to women in the placebo group (median 5.0;
range 3.3–5.6; Fig. 1). The expression of COX-2 was
significantly higher (P < 0.001) in women treated with IMN
(median 16.8; range 8.1–31.7) than in women who had been
given placebo tablets (median 1.5; 0.4–5.8; Fig. 2).
Positive immunostaining for both COX-1 and -2 was
found in smooth muscle of the vessel wall, in bundles of
stromal smooth muscle, and in glandular and squamous
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epithelium (Fig. 3). In addition, immunopositive cells,
probably representing inflammatory cells, were observed as
isolated cells or as clusters of cells. No difference in
distribution of COX-1 positive cells or staining intensity of
these cells was observed between the two groups. Although
the number of immunopositive cells per visual area was too
low to make any statistical calculation there was an overall
impression by the two independent observers that the
staining for COX-2, especially in the ‘‘inflammatory’’stromal
cells, was stronger in women treated with IMN as compared
with women given placebo tablets. In sections where the
squamous epithelium happened to be included, staining
intensity was found to be stronger for COX-1 than for COX-2.
4. Discussion
Cervical ripening has been described as a complex
biochemical cascade in which hormones, cytokines,
leucocytes, prostaglandins, nitric oxide, and various other
substances are involved [12,14]. Prostaglandins and NO are
thought to play a fundamental role in cervical ripening, but
the mechanisms regulating these biochemical mediators
have not been clarified.
Previously, it has been shown that intravaginal admin-
istration of 40 mg IMN for 4 h induces cervical ripening at
term [10]. The present study demonstrates that the cervical
expression of COX-2, but not of COX-1, is increased
following intravaginal treatment with the NO donor for 4 h,
as assessed by immunoblotting. This finding indicates that
an interaction between NO and prostaglandin synthesis is
present in the uterine cervix at term. Several studies have
demonstrated that NO can induce the expression of COX-2,
thereby increasing the release of endogenous prostaglandin
[15–19]. Nitric oxide exerts its effects either via cyclic
guanosine monophosphate (cGMP) as a second messenger
or via cGMP-independent pathways. In cervical tissue
specimens obtained from women before surgical termina-
tion of pregnancy in the first trimester, levels of cGMP as
well as COX-2 have been found to be increased following
intravaginal administration of IMN [20].
When immunoblotting is carried out to assess COX
expression it is important to bear in mind that the binding
to COX-antibodies comprises both active and inactive
enzymes. Consequently, the semiquantitative estimation
of the enzymes does not directly relate to enzyme activity.
This means that we can only presume that the increase
in COX-2 expression was due to new enzyme synthesis.
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Fig. 1. Cervical expression of COX-1 in 12 women treated with IMN and in
12 women given placebo tablets (mean  S.E.M.) and representative
immunoblots of COX-1. Lane 1: human COX-1 electrophoresis standard.
Lanes 2–6: IMN. Lanes 7–11: placebo.
Fig. 2. Cervical expression of COX-2 in 12 women treated with IMN and in
12 women given placebo tablets (mean  S.E.M.) and representative
immunoblots of COX-2. Lane 1: human COX-2 electrophoresis standard.
Lanes 2–6: IMN. Lanes 7–11: placebo.
In support of the present results, a recent report demon-
strated that COX-2 mRNA, but not COX-1 mRNA, was
increased at term, as assessed by RT-PCR technique [21].
Immunohistochemistry did not reveal any difference in
cell types that turned out to be COX immunopositive
between the two groups of women. Nevertheless, it was an
overall impression that the staining for COX-2, especially in
interstitial cells, was more intense in women treated with
IMN as compared to women in the placebo group.
The distribution of COX positive cells found in the
present study is similar to the results demonstrated in a
recently published study comparing COX-1 and -2
distribution in cervical tissue specimens obtained from
preterm and term pregnant women [21]. In the latter study,
the expression of both COX-1 and -2 was increased at term.
It therefore seems likely that both COX-1 and -2 are
increasingly expressed towards term, but that NO prefer-
entially has a stimulating effect on COX-2.
In the present as well as the previously cited study [21],
positive immunostaining for COX-1 as well as COX-2 was
found in smooth muscle. In an earlier study, positive staining
for inducible NO synthase was described in cervical smooth
muscle cells at term [6]. While connective tissue constitutes
the main component of the human uterine cervix, smooth
muscle cells constitute only 10–15% of the human uterine
cervix [22]. The role of cervical smooth muscle has only to a
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Fig. 3. Immunohistochemical staining for COX-1 and -2 in cervical specimens obtained from women treated with IMN and women given placebo tablets. Scale
bars = 50 mm. (a) Placebo. Positive staining for COX-1 seen in smooth muscle of blood vessels (arrowhead), stromal smooth muscle (open arrow), and in
stromal interstitial cells (arrow). (b) IMN treatment. Cervical tissue where positive staining for COX-1 is seen in smooth muscle of blood vessels (arrowhead)
and in clusters of interstitial cells in the perivascular space (arrow). (c) Placebo. Positive staining for COX-2 is seen in smooth muscle (arrowhead) and in an
isolated stromal cell (arrow). (d) IMN treatment. Positive staining for COX-2 is seen in smooth muscle of blood vessels (open arrow), stromal smooth muscle
(arrowhead) and in perivascular and stromal cells (arrow). (e) IMN treatment. Positive staining for COX-1 is seen in epithelial cells (arrow). (f) IMN treatment.
Faint positive staining for COX-2 is seen in epithelial cells (arrow).
certain extent been examined and may have been under-
estimated. It has been shown that prostanoids, especially
prostaglandin E2, inhibit contractions of the cervical muscle
in vitro and that the sensitivity to prostaglandin E2 is
increased at term [23]. In addition, relaxing effects of
cervical smooth tissue following administration of NO
donors have been demonstrated in vitro in tissue specimens
obtained from pregnant women [24,25].
Several studies have concluded that prostaglandins can
stimulate the release of NO [19]. In a recent study, it was
reported that misoprostol, a prostaglandin E1 analogue,
stimulates cervical NO release in pregnant women and that
the sensitivity of NO synthesis to misoprostol was enhanced
at term [26]. On the other hand, it has also been shown that
NO stimulates prostaglandin E2 release from cervical tissue
explants and that cultured cervical tissue after in vivo
treatment with IMN increases prostaglandin F2a release
significantly [27,28]. Thus, a chain reaction where the initial
NO stimulation caused by prostaglandin is followed by an
endogenous release of prostaglandin triggered by NO has
been suggested [26]. The interaction between NO and
prostaglandin synthesis indicates a possible joint action of
the two substances which may be of importance for optimal
cervical ripening at term.
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Abstract
Objective: The aim of the study was to investigate the effect of sublingual
nitroglycerin for management of retained placenta and to assess possible adverse
effects of the treatment. Method: Twenty-four women were randomly selected to
receive either 1 mg nitroglycerin or placebo tablets sublingually if intravenous
oxytocin and controlled umbilical cord traction had failed to expel the placenta.
Success rate for delivery of placenta, blood pressure, pulse rate, blood loss, and
various side effects were examined. Result: All 12 women in the nitroglycerin group
had successful delivery of placenta, while removal of placenta was successful in only
one of the 12 women in the placebo group. No adverse effects of clinical importance
were registered. Conclusion: Sublingual nitroglycerin for treatment of retained
placenta seems to be effective without causing serious adverse effects. However,
the definite clinical value needs to be evaluated in larger series of patients.
D 2005 International Federation of Gynecology and Obstetrics. Published by Elsevier
Ireland Ltd. All rights reserved.
1. Introduction
Retained placenta occurs in 2.0—3.3% of all vaginal
deliveries [1,2]. For management of retained
placenta administration of oxycontin to promote
uterine contractions combined with controlled
umbilical cord traction is usually performed. Oxy-
tocin is either administered intravenously or into
the umbilical vein. Since injections of oxytocin into
the umbilical vein in most cases do not reach the
placental bed, the use of an infant nasogastric tube
to thread down the umbilical vein has been
recommended [3]. According to a recent Cochrane
review, umbilical vein injection of diluted oxytocin
via a nasogastric tube appears to be effective for
management of the retained placenta [4]. In one
study, a success rate of 93.3% in delivering retained
placentas was reported using this method [5].
0020-7292/$ - see front matter D 2005 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.
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When this procedure fails, operative manual
removal under anesthesia is necessary. General
anesthesia is often used since it provides both good
analgesia as well as adequate cervico-uterine
relaxation necessary for manual removal of the
placenta. However, general anesthesia is associat-
ed with an increased risk of complications, such as
aspiration pneumonitis, hemodynamic instability
and delayed emergence [6].
Several reports have indicated that intravenous-
ly administered nitroglycerin is effective for suc-
cessful delivery of retained placenta [7,8].
Nitroglycerin is a well-known nitric oxide donor. In
vitro, nitric oxide donors, including nitroglycerin,
induce immediate relaxation of the term pregnant
myometrium as well as the uterine cervix [9—12].
In vivo, rapid uterine relaxation of short duration is
obtained following intravenous injection of 100—
200 Ag nitroglycerin [13].
Since both oxytocin and nitroglycerin have
shown to be beneficial for management of retained
placenta, we decided to use both agents. In
addition, in order to simplify the medical proce-
dure, intravenous oxytocin was combined with
sublingually administered nitroglycerin tablets.
2. Materials and methods
This trial was designed as a prospective, double-
blind, randomized controlled study. Inclusion cri-
teria were uncomplicated singleton pregnancy
with spontaneous vertex delivery of a healthy
child. Exclusion criteria were gestation less than
37 weeks, postpartum hemorrhage requiring im-
mediate intervention, uterine malformation, in-
tolerance to nitroglycerin, maternal age less than
18 years, suspected placental accretism, and
serious maternal disease, defined as daily use of
medication.
During the recruitment period, all women who
underwent vaginal delivery had standard active
management of the third stage of labor according
to written hospital protocols, including intrave-
nous or intramuscular administration of 5 IU
oxytocin (SyntocinonR, Novartis, Ta¨by, Sweden)
within minutes after delivery of the neonate.
Maternal effort was encouraged to expel the
placenta. If this was insufficient, controlled
umbilical cord traction was used. This procedure
involved applying steady, gentle traction to the
cord with a Kelly clamp while providing counter
tracking against the uterine fundus. If the pla-
centa still remained undelivered 30 min after
delivery of the neonate an additional dose of 10
IU oxytocin was given intravenously to induce
more efficient uterine contractions and thus
promote placental separation. It has previously
been indicated that a third stage of more than 30
min should be regarded as a prolonged third
stage, because complications arise when this
interval is exceeded [1]. Five minutes after
administration of oxytocin another controlled
umbilical cord traction for 5 min was carried
out. Women were considered eligible for recruit-
ment to the study if the placenta remained
undelivered 40 min after completion of the
second stage of labor, despite additional admin-
istration of 10 IU oxytocin followed by controlled
umbilical cord traction.
Once the diagnosis of retained placenta had
been made, a rapidly running intravenous infu-
sion was initiated and all women were hemody-
namically monitored. A total number of 24
women were recruited for the study. The women
were randomized to either of the two groups:
(1) 1 mg of nitroglycerin tablets (two 0.5 mg
tablets) (NitromexR, Alpharma AB, Stockholm,
Sweden) or (2) two placebo tablets of similar
design as the nitroglycerin tablets. Randomiza-
tion was carried out by means of numbered
opaque, sealed envelopes, prepared with ran-
dom-number tables and was performed by a
research nurse. The tablets were administered
sublingually approximately 50 min after child
delivery. Neither the participating women nor
the obstetrician on duty were aware of the
agent administered. Five minutes after adminis-
tration of either nitroglycerin or placebo tablets,
controlled cord traction was again performed for
a maximum duration of 5 min. No extra anes-
thesia was given during this procedure, except
inhalation of nitrous gas, if wanted by the
women. If placenta was delivered by means of
controlled umbilical cord traction the procedure
was regarded as successful. Additional intrave-
nous oxytocin, usually 5 IU, was given once the
placenta had been delivered.
If the placenta remained undelivered, operative
manual removal was conducted under either re-
gional (epidural or spinal) or general anesthesia. To
reduce postoperative hemorrhage, 5 IU of oxytocin
was routinely administered intravenously at the
end of the operative manual removal. Maternal
blood pressure and pulse rate were measured
immediately prior to the sublingual administration
of either nitroglycerin or placebo tablets. These
measurements were repeated 15 min later for
assessment of possible hemodynamic effects
caused by the nitroglycerin tablets. Blood loss
during the third stage of delivery was registered
in each case. In addition, all the women completed
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a questionnaire about possible side effects of
nitroglycerin.
2.1. Statistical analysis
A sample size of 24 women (12 in each group) was
calculated to yield a power of 90% at the 5%
significance level when assuming a success rate of
80% in the treated group compared to a 20% success
rate in the placebo group. MeanFSD and range
were calculated for descriptive purposes. For
statistical comparison the Student’s t-test was used
for continuous variables and the Chi squared test
was used for dichotomous variables.
3. Results
No significant difference in mean maternal age,
gestational age or parity was found between
women treated with oxytocin+nitroglycerin ver-
sus women treated with oxytocin+placebo (Ta-
ble 1). All 12 women in the nitroglycerin group
had successful delivery of placenta within 5 min
of controlled cord traction. Of the 12 women
given placebo tablets only one woman had
successful delivery of placenta by means of
controlled cord traction. In the other eleven
women in this group operative manual removal
of placenta under regional or general anesthesia
was necessary.
In women treated with nitroglycerin, a signifi-
cant decrease in systolic and diastolic blood
pressures was measured 15 min after administra-
tion of the drug as compared to immediately before
administration of nitroglycerin (Table 2). In the
placebo group a significant decrease in systolic
blood pressure was registered. While a slight
increase in pulse rate 15 min after administration
of nitroglycerin was registered, a significant de-
crease in pulse rate was measured in the placebo
group (Table 3).
Mean blood loss was found to be significantly
higher in the placebo group versus the nitroglycerin
group (Table 1). None of the women treated with
nitroglycerin had a blood loss of more than 650 mL.
Mean blood loss in the two groups was similar when
measured before operative manual removal of the
placenta was carried out, in cases where controlled
umbilical cord traction had failed. Thus, operative
manual removal of the placenta under regional or
general anesthesia resulted in an additional mean
blood loss of 275F101.1 mL (range 50—400 mL).
However, the blood loss did not cause any clinical
Table 1 Characteristics and clinical data of women participating in the study
Oxytocin+nitroglycerin Oxytocin+placebo P-value
(n =12) (n =12)
Maternal age (years) 33.17F4.78 (26, 39) 31.67F3.94 (27, 40) NS
Gestational age (weeks) 281.83F8.15 (265, 292) 283.50F9.39 (264, 294) NS
Nulliparous (n) 8 8
Multiparous (n) 4 4
Epidural anesthesia (n) 6 7
Successful delivery of placenta (n) 12 1 b0.0001
Failed delivery of placenta (n) 0 11 b0.0001
Total blood loss (mL) 400F108.71 (250, 650) 662.50F144.80 (400, 900)a b0.0001
Data are shown as meanFSD, range.
a Intraoperative blood loss at the operating theater included.
Table 2 Hemodynamic measurements in women immediately before administration of either nitroglycerin tablets
or placebo tablets and 15 min after administration of tablets
Pre-nitroglycerin Post-nitroglycerin P-value
(n =12) (n =12)
Systolic BP (mm Hg) 119.17F7.33 (110, 130) 112.92F7.82 (100, 125) 0.003
Diastolic BP (mm Hg) 76.25F5.69 (70, 85) 71.25F4.33 (65, 80) 0.001
Pulse (bpm) 76.67F5.35 (70, 86) 78.67F4.21 (74, 86) NS
Pre-placebo Post-placebo P-value
(n =12) (n =12)
Systolic BP (mm Hg) 117.08F7.22 (105, 130) 114.58F6.20 (105, 120) 0.026
Diastolic BP (mm Hg) 72.92F7.53 (60, 85) 71.67F6.51 (60, 80) NS
Pulse rate (bpm) 75.50F5.73 (66, 86) 71.50F3.73 (62, 76) 0.004
Data are shown as meanFSD, range. NS, nonsignificant.
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complications in any of the women and no blood
transfusions were given.
The most frequent symptomatic side effect of
nitroglycerin was headache, experienced by four
women. Two of these women described the head-
ache as mild, while the two other women had
headache of moderate intensity. In the placebo
group, one woman reported headache of moderate
intensity within 10 min following administration of
placebo tablets. In all women, the headache
disappeared spontaneously within 2 h. One woman
in the nitroglycerin group and one woman in the
placebo group reported hot flushes. No other
symptomatic side effects were reported.
4. Discussion
The present study indicates that sublingual nitro-
glycerin is both effective and safe in cases of
prolonged third stage labour. The finding that
intravenously administered nitroglycerin promotes
placental separation has previously been de-
scribed in several reports [8,13—16]. When nitro-
glycerin is injected intravenously uterine
relaxation usually occurs within 45—60 s and the
relaxation normally lasts no longer than 2 min
[13]. In contrast, sublingual nitroglycerin reaches
its maximum plasma concentration within 5 min
with a half-life of approximately 3 min [17].
Although not examined in detail in the present
study, a slight increase in uterine bleeding
indicating uterine relaxation and placental sepa-
ration was observed in some of the women about
3 min after administration of nitroglycerin
tablets. This observation is in agreement with
the fact that vasorelaxation induced by sublingual
nitroglycerin for treatment of angina pectoris
normally occurs within 2—3 min following sublin-
gual administration. Furthermore, a dose of 1 mg
nitroglycerin, as used in the present study, is a
standard dose for treatment of angina pectoris.
The potential risk that a dose of 1 mg nitroglyc-
erin would induce hypotension of clinical impor-
tance seems to be ruled out. In the present study,
systolic as well as diastolic blood pressures were
significantly decreased 15 min after administration
of nitroglycerin. In the same group of women a
slight, but nonsignificant increase in pulse rate was
measured. The rapidly running intravenous infusion
may to a certain extent have compensated for a
further decrease in blood pressure.
Another important clinical aspect of sublingual
nitroglycerin for management of retained placenta
is the possibility that it could induce prolonged
uterine relaxation, thereby causing increased intra-
partum blood loss. In the present study, no
prolonged uterine relaxation following administra-
tion of sublingual nitroglycerin was registered.
Following injection of oxytocin immediately after
placental delivery recovery of uterine tone oc-
curred in all women without any delay. A rapid
reversal of uterine relaxation has also been de-
scribed to take place when intravenous nitroglyc-
erin is administered during obstetric emergencies
[8,13,16]. Thus, the risk of nitroglycerin induced
uterine hemorrhage seems to be low. However,
nitroglycerin should never be administered in cases
of hypovolemia or postpartum hemorrhage. When
nitroglycerin is given for management of retained
placenta a rapidly running intravenous infusion is
mandatory and ephedrine should always be avail-
able in case of a hypotensive reaction.
Little is known about the pathophysiology of
retained placenta. Dynamic ultrasonographic imag-
ing of the third stage of labor has demonstrated
that retro-placental myometrial contractions are
necessary for placental separation and that lack of
retro-placental contractions results in retained
placenta [18]. Herman et al. suggested that
placental separation is caused by shearing forces
between a passive placenta and active placenta-
site uterine muscle, which diminish placental site
surface area and thus tear septa in the spongiosa.
They hypothesized that dynamic interrelationships
between the decidua in the placenta-site and
corresponding uterine smooth muscle control pla-
cental separation. Recently it was demonstrated
that placental anchoring villi are able to contract
and relax and that this ability is under the control
Table 3 Comparison between differences in hemodynamic parameters in women receiving either nitroglycerin or
placebo tablets (measurements obtained 15 min after administration of tablets minus measurements obtained prior
to administration of tablets)
Nitroglycerin Placebo P-value
(n =12) (n =12)
Difference in systolic BP (mm Hg) 6.25F5.69 (15, 5) 2.50F3.37 (10, 0) NS
Difference in diastolic BP (mm Hg) 5.00F3.69 (10, 0) 1.25F3.11 (5, 5) 0.013
Difference in pulse rate (bpm) 2.00F3.52 (4, 6) 4.00F3.81 (10, 2) 0.001
Data are shown as meanFSD, range. NS, nonsignificant.
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of nitric oxide [19]. This mechanism may be of
importance for the regulation of intraplacental
volume, but it could also play a role in placental
separation. In another recently published study it
was demonstrated that oxytocin exerts an overall
stimulating effect on nitric oxide release by fetal
membranes at term and that this stimulating effect
is more marked after labour than before labour
[20]. An interaction between oxytocin and nitric
oxide, as demonstrated in the latter study, could
play a role in promoting placental separation.
The results of the present trial are extremely
promising, but in line with previous reports where
intravenous nitroglycerin has been used for man-
agement of retained placenta. So far, twenty-nine
women with retained placenta have been treated
according to the presented treatment regimen. In
only one of these cases was operative manual
removal under anesthesia necessary. Sequential
administration of oxytocin and nitroglycerin for
management of retained placenta should therefore
be considered in women who are hemodynamically
stable and with no signs of postpartum hemorrhage.
However, larger studies are necessary to identify
the exact role of nitroglycerin for the management
of retained placenta and to establish standard
treatment protocols.
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